
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">EXCLI J</journal-id><journal-id journal-id-type="iso-abbrev">EXCLI J</journal-id><journal-id journal-id-type="publisher-id">EXCLI J</journal-id><journal-title-group><journal-title>EXCLI Journal</journal-title></journal-title-group><issn pub-type="epub">1611-2156</issn><publisher><publisher-name>Leibniz Research Centre for Working Environment and Human Factors</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28507465</article-id><article-id pub-id-type="pmc">5427481</article-id><article-id pub-id-type="publisher-id">2016-847</article-id><article-id pub-id-type="doi">10.17179/excli2016-847</article-id><article-id pub-id-type="publisher-id">Doc174</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>L&#x000f3;pez-Flores</surname><given-names>Luis A.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>P&#x000e9;rez-Rubio</surname><given-names>Gloria</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Falf&#x000e1;n-Valencia</surname><given-names>Ramc&#x000e9;s</given-names></name><xref ref-type="corresp" rid="COR1">*</xref><xref ref-type="aff" rid="A1">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas</aff><author-notes><corresp id="COR1">*To whom correspondence should be addressed: Ramc&#x000e9;s Falf&#x000e1;n-Valencia, Laboratorio HLA, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas. Calzada de Tlalpan 4502. Secci&#x000f3;n XVI. Tlalpan, 14080 M&#x000e9;xico City. M&#x000e9;xico. Phone +52 55 5487 1700 ext. 5152, E-mail: <email>rfalfanv@iner.gob.mx</email></corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>16</volume><fpage>174</fpage><lpage>196</lpage><history><date date-type="received"><day>19</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>13</day><month>2</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2017 L&#x000f3;pez-Flores et al.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p><!--CREATIVE COMMONS-->This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>) You are free to copy, distribute and transmit the work, provided the original author and source are credited.</license-p></license></permissions><self-uri xlink:type="simple" xlink:href="http://www.excli.de/vol16/Falfan-Valencia_06032017_proof.pdf">This article is available from http://www.excli.de/vol16/Falfan-Valencia_06032017_proof.pdf</self-uri><abstract><p>Tobacco consumption has become a major public health issue, which has motivated studies to identify and understand the biological processes involved in the smoking behavior for prevention and smoking cessation treatments. <italic>CYP2A6</italic> has been identified as the main gene that codifies the enzyme that metabolizes nicotine. Many alleles have been identified after the discovery of <italic>CYP2A6</italic>, suggesting a wide interethnic variability and a diverse smoking behavior of the allele carrying individuals. The main purpose of this review is to update and highlight the effects of the <italic>CYP2A6</italic> gene variability related to tobacco consumption reported from diverse human populations. The review further aims to consider <italic>CYP2A6</italic> in future studies as a possible genetic marker for the prevention and treatment of nicotine addiction. Therefore, we analyzed several population studies and their importance at addressing and characterizing a population using specific parameters. Our efforts may contribute to a personalized system for detecting, preventing and treating populations at a higher risk of smoking to avoid diseases related to tobacco consumption.</p></abstract><kwd-group><kwd>CYP2A6</kwd><kwd>ethnic differences</kwd><kwd>genetic polymorphism</kwd><kwd>tobacco consumption</kwd><kwd>nicotine metabolism</kwd><kwd>nicotine addiction</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Tobacco consumption has become an epidemic affecting more than 1,000 million people worldwide and is considered the main cause of avoidable death causing approximately 6 million premature deaths each year (WHO, 2011[<xref rid="R146" ref-type="bibr">146</xref>]). Thus, tobacco consumption is a public health issue combined with economic losses; it has motivated studies for identifying and understanding the biological processes involved in the smoking behavior for prevention and smoking cessation treatments (Bierut et al, 2014[<xref rid="R15" ref-type="bibr">15</xref>]).</p><p>Among cigarette compounds, nicotine is responsible for causing dependence by stimulating the smoker and allowing the other compounds to access the body, causing chronic harmful effects and tobacco-related diseases.</p><p>Tobacco consumption is caused by environmental, psychosocial and genetic factors (Bierut, et al., 2014[<xref rid="R15" ref-type="bibr">15</xref>]). Previous studies have identified genes encoding proteins that influence nicotine addictive behavior due to their effect on the cerebral neurotransmission pathways (Al Koudsi and Tyndale, 2005[<xref rid="R4" ref-type="bibr">4</xref>]; Arinami et al., 2000[<xref rid="R5" ref-type="bibr">5</xref>]; Verde Rello and Santiago Dorrego, 2013[<xref rid="R141" ref-type="bibr">141</xref>]). Moreover, some gene products are involved in nicotine response as receptors and metabolizers (Hukkanen et al., 2005[<xref rid="R55" ref-type="bibr">55</xref>]; Verde Rello and Santiago Dorrego, 2013[<xref rid="R141" ref-type="bibr">141</xref>]). P&#x000e9;rez-Rubio et al. (2015[<xref rid="R108" ref-type="bibr">108</xref>]) have reviewed this subject in detail. In the metabolizers group, the <italic>CYP2A6</italic> gene plays an important role. Its protein product (by the same name) is the principal enzyme responsible for nicotine metabolism to cotinine and other sub-products in the human body. However, more than 45 alleles have been discovered suggesting wide interindividual and interethnic variety.</p><p>The main purpose of this review is to update and highlight the effects of the genetic polymorphisms of <italic>CYP2A6</italic> related to tobacco consumption reported in diverse human populations. Moreover, we aimed to consider these polymorphisms in future studies as possible genetic markers for the prevention and treatment of nicotine addiction.</p></sec><sec><title>Biological Function of CYP2A6 in Smoking</title><p>The CYP2A6 enzyme belongs to the enzyme superfamily known as the cytochrome P450 system (CYP450), also classified in the drug metabolizing enzymes group. These enzymes are found in the endoplasmic reticulum of the cells of some tissues in the body, particularly in the liver. Moreover, they are phase I enzymes responsible for metabolizing more than 80 % of drugs such as xenobiotics and endogen products in the body (Evans and Relling, 2004[<xref rid="R33" ref-type="bibr">33</xref>]; Ingelman-Sundberg, 2004[<xref rid="R56" ref-type="bibr">56</xref>]).</p><p>CYP2A6 is found mainly in the liver and is approximately 5-10 % of the total CYP450 content (Shimada et al., 1996[<xref rid="R120" ref-type="bibr">120</xref>]; Yamano et al., 1990[<xref rid="R148" ref-type="bibr">148</xref>]), although it has also been found to be expressed in the nasal mucosa, trachea, bronchi, lungs, sinuses and several brain regions (Bhagwat et al., 2000[<xref rid="R14" ref-type="bibr">14</xref>]; Chiang et al., 2012[<xref rid="R22" ref-type="bibr">22</xref>]; Crawford et al., 1998[<xref rid="R24" ref-type="bibr">24</xref>]; Ding and Kaminsky, 2003[<xref rid="R29" ref-type="bibr">29</xref>]; Mac&#x000e9; et al., 1998[<xref rid="R78" ref-type="bibr">78</xref>]).</p><p>CYP2A6 has demonstrated to be involved in the metabolism of some endogen and exogen substrates such as precarcinogenic and carcinogenic compounds, as well as some toxins and drugs including nicotine.</p><p>CYP2A6 has been particularly important in tobacco consumption because of its involvement in nicotine metabolism. Nicotine is the main compound in tobacco responsible for the development of cigarette addiction by stimulating nicotinic cholinergic receptors (nAChR) that release neurotransmitters in the brain and cause a pleasant sensation in the smoker. The nicotine availability in the body is mediated by biological factors, mainly those related to its metabolism. Smokers tend to consume the same amount of nicotine each day to acquire the desired effects by modulating their smoking behavior to adjust nicotine availability for the purpose of regulating nicotine levels in the body (Benowitz, 1992[<xref rid="R10" ref-type="bibr">10</xref>]).</p><p>It has been reported that CYP2A6 is the main enzyme involved in the nicotine oxidation to cotinine. CYP2A6 catalyzes approximately 80 % (55-92 %) of this reaction via C-oxidation in addition to other metabolic pathways for nicotine and its metabolites (Benowitz and Jacob III, 1994[<xref rid="R11" ref-type="bibr">11</xref>]; Messina et al., 1997[<xref rid="R83" ref-type="bibr">83</xref>]; Nakajima et al., 1996[<xref rid="R94" ref-type="bibr">94</xref>]). Some other enzymes of CYP450 contribute to a lesser degree to nicotine metabolism such as CYP2B6, CYP2A13, CYP2D6 and CYP2E1 (mentioned in the order of relevance).</p><p>These biological products interact directly with nicotine to affect physiological brain processes (e.g., nAChR) and are inactivated and removed from the body (e.g., CYP450 enzymes) making their genes ideal candidates for altering smoking behavior (Malaiyandi et al., 2005[<xref rid="R82" ref-type="bibr">82</xref>]).</p></sec><sec><title>CYP2A6 Genetic Variants</title><p>The <italic>CYP2A6</italic> gene has a 6 kb extension length, and it is composed of 9 exons, which encode for a 494 amino-acid product (Fernandez-Salguero et al., 1995[<xref rid="R34" ref-type="bibr">34</xref>]). It is located in the chromosomal band 19q13.2, where other CYP450 gene subfamilies (<italic>CYP2B</italic>, <italic>CYP2F</italic>, <italic>CYP2G</italic>, <italic>CYP2S</italic>, and <italic>CYP2T</italic>) are also present. The CYP2A subfamily cluster includes the <italic>CYP2A6</italic>, <italic>CYP2A7</italic>, and <italic>CYP2A13</italic> genes and other pseudogenes (Hoffman et al., 2001[<xref rid="R52" ref-type="bibr">52</xref>]).</p><p>The <italic>Human CYP-Allele Nomenclature Database</italic> (HCAND) (<ext-link ext-link-type="uri" xlink:href="http://www.cypalleles.ki.se">http://www.cypalleles.ki.se</ext-link>) was created in 1999 for the identification and characterization of <italic>CYP2A6</italic> alleles (and other CYP450 genes). This database consists of a committee for unifying and assigning nomenclature for the already discovered alleles and alleles to be discovered in the future (Sim and Ingelman-Sundberg, 2010[<xref rid="R121" ref-type="bibr">121</xref>], 2013[<xref rid="R122" ref-type="bibr">122</xref>]). </p><p>To date, 42 well-characterized alleles and some haplotypes that are uncharacterized (&#x0201c;CYP2A6 allele nomenclature,&#x0201d; 2014[<xref rid="R25" ref-type="bibr">25</xref>]) have been identified. These alleles are determined according to the origins of their mutation(s), such as gene conversion, gene deletion, gene duplication and/or single nucleotide polymorphism (SNP). The gene mutations are summarized in Figure 1<xref ref-type="fig" rid="F1">(Fig. 1)</xref>.</p><p>The wild-type allele that is considered as a reference is <italic>CYP2A6*1A</italic> (Yamano et al., 1990[<xref rid="R148" ref-type="bibr">148</xref>]). <italic>CYP2A6*1B</italic> consists of a 58 bp gene conversion with <italic>CYP2A7</italic> in the <italic>CYP2A6 </italic>3' UTR region (Ariyoshi et al., 2000[<xref rid="R8" ref-type="bibr">8</xref>]; Yamano et al., 1990[<xref rid="R148" ref-type="bibr">148</xref>]). <italic>In vitro </italic>and<italic> in vivo a</italic>ssays have shown that the <italic>CYP2A6 </italic>3' UTR region has more enzymatic activity and RNA stabilization than the reference allele (Ho et al., 2009[<xref rid="R49" ref-type="bibr">49</xref>]; Wang et al, 2006[<xref rid="R143" ref-type="bibr">143</xref>]; Yoshida et al., 2002[<xref rid="R150" ref-type="bibr">150</xref>]). However, several haplotypes contain this gene conversion and other noncoding genetic changes and have been designated <italic>CYP2A6*1B1-B17</italic> (Ariyoshi et al., 2000[<xref rid="R8" ref-type="bibr">8</xref>]; Haberl et al., 2005[<xref rid="R46" ref-type="bibr">46</xref>]; Mwenifumbo et al., 2007[<xref rid="R89" ref-type="bibr">89</xref>], 2008[<xref rid="R87" ref-type="bibr">87</xref>], 2010[<xref rid="R90" ref-type="bibr">90</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Pitarque et al., 2004[<xref rid="R111" ref-type="bibr">111</xref>]; Yamano et al., 1990[<xref rid="R148" ref-type="bibr">148</xref>]). Moreover, it has been determined that other wild-type alleles, named <italic>CYP2A6*1D-L</italic>, that have genetic changes in coding, noncoding and regulatory regions (Mwenifumbo et al., 2008[<xref rid="R87" ref-type="bibr">87</xref>], 2010[<xref rid="R90" ref-type="bibr">90</xref>]; Nakajima et al, 2004[<xref rid="R95" ref-type="bibr">95</xref>]; Pitarque et al., 2004[<xref rid="R111" ref-type="bibr">111</xref>]; von Richter et al., 2004[<xref rid="R142" ref-type="bibr">142</xref>]; Yamano et al., 1990[<xref rid="R148" ref-type="bibr">148</xref>]).</p><p><italic>CYP2A6*2</italic> consists of a missense mutation of 1799T&#x0003e;A, causing an amino acid change of Leu160His in the enzyme. Thus, the protein does not incorporate the heme group, inactivating the enzyme for <italic>in vitro</italic> and <italic>in vivo</italic> assays (Benowitz et al., 1995[<xref rid="R12" ref-type="bibr">12</xref>]; Hadidi et al., 1997[<xref rid="R47" ref-type="bibr">47</xref>]; Oscarson, et al., 1999[<xref rid="R103" ref-type="bibr">103</xref>]; Yamano et al., 1990[<xref rid="R148" ref-type="bibr">148</xref>]).</p><p><italic>CYP2A6*3</italic> is presumed to be a gene conversion of <italic>CYP2A6</italic> to <italic>CYP2A7</italic>, which results in an inactive enzyme; however, the methodology for their detection, function, and allelic frequency has been controversial (Fernandez-Salguero et al., 1995[<xref rid="R34" ref-type="bibr">34</xref>]; Oscarson et al., 1998[<xref rid="R100" ref-type="bibr">100</xref>]; Yamano et al., 1990[<xref rid="R148" ref-type="bibr">148</xref>]).</p><p><italic>CYP2A6*4</italic> consists of a homologous unequal crossover with <italic>CYP2A7</italic> on several positions (<italic>CYP2A6*4A-F</italic>), which leads to a whole gene deletion causing loss of enzymatic activity (Kitagawa et al., 1999[<xref rid="R62" ref-type="bibr">62</xref>]; Nakajima et al., 2000[<xref rid="R93" ref-type="bibr">93</xref>], 2001[<xref rid="R92" ref-type="bibr">92</xref>]; Nunoya et al., 1999[<xref rid="R97" ref-type="bibr">97</xref>]).</p><p><italic>CYP2A6*5</italic> contains a missense mutation, 6582G&#x0003e;T, creating a Gly479Val amino acid change and resulting in a lack of enzyme function (Oscarson et al., 1999[<xref rid="R103" ref-type="bibr">103</xref>]).</p><p><italic>CYP2A6*6</italic> contains a missense mutation, 6582G&#x0003e;T, which creates an Arg128Gln amino acid change causing lower enzymatic activity of the enzyme (Kitagawa et al., 2001[<xref rid="R63" ref-type="bibr">63</xref>]).</p><p><italic>CYP2A6*7</italic> contains a missense mutation, 6558G&#x0003e;A, which produces an Ile471Thr amino acid change that decreases the enzymatic activity to metabolize some substrates for <italic>in vivo</italic> and <italic>in vitro</italic> assays (Ariyoshi et al, 2001[<xref rid="R7" ref-type="bibr">7</xref>]; Uno et al., 2013[<xref rid="R138" ref-type="bibr">138</xref>]; Xu et al., 2002[<xref rid="R147" ref-type="bibr">147</xref>]).</p><p><italic>CYP2A6*8</italic> contains a missense mutation, 6600G&#x0003e;T, creating an amino acid change in Arg485Leu; however, the mutation's effect apparently does not change the enzymatic activity (Xu et al., 2002[<xref rid="R147" ref-type="bibr">147</xref>]).</p><p><italic>CYP2A6*9</italic> contains a point mutation, -48T&#x0003e;G, on the TATA box located in the gene promoter, which results in a decrease of more than 50 % of the enzymatic activity for <italic>in vitro </italic>and<italic> in vivo</italic> assays (Pitarque et al., 2001[<xref rid="R110" ref-type="bibr">110</xref>]; Yoshida et al., 2003[<xref rid="R149" ref-type="bibr">149</xref>]). There have been identified two subtypes of this allele: <italic>CYP2A6*9A</italic>, which contains an additional -1013A&#x0003e;G point mutation (von Richter et al., 2004[<xref rid="R142" ref-type="bibr">142</xref>]), and <italic>CYP2A6*9B</italic>, which contains the point mutations -1680A&#x0003e;G, -1301A&#x0003e;C, -1289G&#x0003e;A, 1620T&#x0003e;C, 1836G&#x0003e;T, 6354T&#x0003e;C and 6692C&#x0003e;G (Haberl et al., 2005[<xref rid="R46" ref-type="bibr">46</xref>]).</p><p><italic>CYP2A6*10</italic> contains two point mutations, similar to the <italic>CYP2A6*7</italic> and <italic>CYP2A6*8</italic> alleles. These point mutations decrease the enzymatic activity dramatically and make it completely inactive for some substrates (Xu et al., 2002[<xref rid="R147" ref-type="bibr">147</xref>]).</p><p><italic>CYP2A6*11</italic> contains a missense mutation, 3391T&#x0003e;C, which results in the amino acid change of Ser224Pro, decreasing the enzymatic activity (Daigo et al., 2002[<xref rid="R26" ref-type="bibr">26</xref>]).</p><p><italic>CYP2A6*12A</italic> originated by the unequal crossover between <italic>CYP2A6 </italic>and<italic> CYP2A7</italic>, which resulted in a hybrid allele at the 5' UTR and exons 1- 2 belonging to <italic>CYP2A7</italic> and from the 3<sup>rd</sup> to 9<sup>th</sup> exon belonging to <italic>CYP2A6</italic>. This generates a 10 amino acid substitution compared to the reference allele (Oscarson et al., 2002[<xref rid="R101" ref-type="bibr">101</xref>]). Later, several SNPs were discovered in the same allele, which generates two subvariants (<italic>CYP2A6*12B-C</italic>) (Haberl et al., 2005[<xref rid="R46" ref-type="bibr">46</xref>]). These alleles are classified as null enzymatic activity (Bloom et al., 2011[<xref rid="R17" ref-type="bibr">17</xref>]).</p><p><italic>CYP2A6*13 </italic>has two point mutations: the first at -48T&#x0003e;G in the TATA box of the promoter and the second at 13G&#x0003e;A changes the amino acid Gly5Arg. The enzymatic activity is decreased (Kiyotani et al., 2002[<xref rid="R64" ref-type="bibr">64</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]).</p><p><italic>CYP2A6*14</italic> has the missense mutation 86G&#x0003e;A and changes the Ser29Asn amino acid chain; however, this does not affect the enzymatic activity (Kiyotani et al., 2002[<xref rid="R64" ref-type="bibr">64</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]).</p><p><italic>CYP2A6*15</italic> is the product of two point mutations: the first at -48T&#x0003e;G in the TATA box of the promoter and the second at 2134 A&#x0003e;G, which results in an amino acid change of Lys194Glu (Kiyotani et al., 2002[<xref rid="R64" ref-type="bibr">64</xref>]). However, this enzyme does not show differences in substrate metabolism (Tiong et al., 2014[<xref rid="R134" ref-type="bibr">134</xref>]; 2010[<xref rid="R135" ref-type="bibr">135</xref>]).</p><p><italic>CYP2A6*16</italic> has a missense mutation at 2161C&#x0003e;A, which makes an amino acid change of Arg203Ser (Kiyotani et al., 2002[<xref rid="R64" ref-type="bibr">64</xref>]); however, it does not cause a defect in the enzymatic activity (Ho et al., 2008[<xref rid="R50" ref-type="bibr">50</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Tiong et al., 2014[<xref rid="R134" ref-type="bibr">134</xref>], 2010[<xref rid="R135" ref-type="bibr">135</xref>]).</p><p><italic>CYP2A6*17</italic> shows several point mutations, 51G&#x0003e;A, 209C&#x0003e;T, 1779G&#x0003e;A, 4489C&#x0003e;T, 5065G&#x0003e;A, 5163G&#x0003e;A, 5717C&#x0003e;T and 5825A&#x0003e;G, which result in the amino acid change Val365Met and cause a decrease in the enzymatic activity of the allele (Fukami et al., 2004[<xref rid="R41" ref-type="bibr">41</xref>]).</p><p><italic>CYP2A6*18</italic> has three subvariants that share the missense mutation at 5886A&#x0003e;T and the amino-acid change Tyr392Phe.<italic> CYP2A6*18A</italic> only has that point mutation while <italic>CYP2A6*18B</italic> also has synonymous substitutions at 51G&#x0003e;A, 5684T&#x0003e;C and 5702T&#x0003e;C. <italic>CYP2A6*18C</italic> also has the point mutations at -1680A&#x0003e;G, -1579T&#x0003e;C, -1464A&#x0003e;T, -1301A&#x0003e;C, -1289G&#x0003e;A, -1013A&#x0003e;G, 1620T&#x0003e;C, 5668A&#x0003e;T and 6692C&#x0003e;G. The enzymatic activity of this allele tends to be specific according to the substrate (Fukami et al., 2005[<xref rid="R38" ref-type="bibr">38</xref>]; Haberl et al., 2005[<xref rid="R46" ref-type="bibr">46</xref>]).</p><p><italic>CYP2A6*19</italic> is produced by the point mutations at 5668A&#x0003e;T, 6354T&#x0003e;C, and 6558T&#x0003e;C and a gene conversion at the 3'UTR with <italic>CYP2A7</italic>, which correspond to the amino acid changes of Tyr392Phe and Ile471Thr, decreasing the enzymatic activity (Fukami et al., 2005[<xref rid="R38" ref-type="bibr">38</xref>]).</p><p><italic>CYP2A6*20</italic> has a frameshift mutation at nucleotides 2140 and 2141, which displaces the frameshift from the codon 196 to stop prematurely at 220 codons. In addition, it has three point mutations at 51G&#x0003e;A, 5684T&#x0003e;C and 6692C&#x0003e;G. These mutations produce a loss-of-function enzyme (Fukami et al., 2005[<xref rid="R37" ref-type="bibr">37</xref>]; Mwenifumbo et al., 2008[<xref rid="R87" ref-type="bibr">87</xref>]).</p><p><italic>CYP2A6*21</italic> is the result of two point mutations: 51G&#x0003e;A and 6573A&#x0003e;G, which produce an amino acid change Lys476Arg (Haberl et al., 2005[<xref rid="R46" ref-type="bibr">46</xref>]). However, the functional effect of the enzyme is still under discussion because it has been reported that <italic>in vivo </italic>assays show differences according to the study population (Al Koudsi et al., 2006[<xref rid="R3" ref-type="bibr">3</xref>]; Mwenifumbo et al., 2008[<xref rid="R87" ref-type="bibr">87</xref>]) and <italic>in vitro</italic> assays show normal enzymatic activity (Tiong et al., 2014[<xref rid="R134" ref-type="bibr">134</xref>], 2010[<xref rid="R135" ref-type="bibr">135</xref>]).</p><p><italic>CYP2A6*22</italic> is the result of three point mutations: 51G&#x0003e;A, 1794C&#x0003e;G and 1798C&#x0003e;A, which cause the amino acid changes Asp158Glu and Leu160Ile (Haberl et al., 2005[<xref rid="R46" ref-type="bibr">46</xref>]). These mutations reduce the enzyme affinity to the substrates; <italic>CYP2A6*22</italic> has 39 % of the enzyme activity compared to the reference allele (Tiong et al., 2014[<xref rid="R134" ref-type="bibr">134</xref>], 2010[<xref rid="R135" ref-type="bibr">135</xref>]).</p><p><italic>CYP2A6*23</italic> contains a point mutation at 2161C&#x0003e;T that corresponds to the amino acid change Arg203Cys; this decreases the enzymatic activity to 19 % compared to the reference allele (Ho et al., 2009[<xref rid="R49" ref-type="bibr">49</xref>], 2008[<xref rid="R50" ref-type="bibr">50</xref>]).</p><p><italic>CYP2A6*24</italic> has two subvariants, among which <italic>CYP2A6*24A</italic> has the following point mutations: -1301A&#x0003e;C, -1289G&#x0003e;A, -1013A&#x0003e;G, 51G, 578A&#x0003e;G, 594G&#x0003e;C, 720G&#x0003e;A, 1137C&#x0003e;G, 1620T&#x0003e;C, 2483G&#x0003e;A, 3225A&#x0003e;G, 5668A, 6218A&#x0003e;G, 6282A&#x0003e;G, 6293T&#x0003e;C, 6354T&#x0003e;C, 6458A&#x0003e;T, , 6782C&#x0003e;G and 7160A&#x0003e;G, as well as a gene conversion in the 3'UTR of 58 bp. However, <italic>CYP2A6*24B</italic> has a 1381_1382CT&#x0003e;TC substitution and 1481_1486delCTCTCT deletion. These mutations cause the amino acid changes Val110Leu and Asn438Tyr, which encode a loss-of-function enzyme (Mwenifumbo et al., 2008[<xref rid="R87" ref-type="bibr">87</xref>]).</p><p><italic>CYP2A6*25</italic> is the result of several point mutations, some of them in 5'UTR: -1301A&#x0003e;C, -1289G&#x0003e;A and -745A&#x0003e;G, also 22C&#x0003e;T, 51G, 768A&#x0003e;T, 1620T&#x0003e;C, 1672T&#x0003e;C, 2296C&#x0003e;T, 2483G&#x0003e;A, 2605G&#x0003e;A, 2921G&#x0003e;A, 2994T&#x0003e;C, 4636A&#x0003e;C, 5668A, 6586T&#x0003e;C, 6692C&#x0003e;G and 7160A&#x0003e;G that result in the amino acid change of Phe118Leu (Mwenifumbo et al., 2008[<xref rid="R87" ref-type="bibr">87</xref>]), it has been shown that its enzymatic activity is decreased in some substrates (Ho et al., 2009[<xref rid="R49" ref-type="bibr">49</xref>]; Mwenifumbo et al., 2008[<xref rid="R87" ref-type="bibr">87</xref>]; Uno et al., 2013[<xref rid="R138" ref-type="bibr">138</xref>]).</p><p><italic>CYP2A6*26</italic> is produced by the following point mutations: -1301A&#x0003e;C, -1289G&#x0003e;A, -745A&#x0003e;G, 22C&#x0003e;T, 51G, 1165G&#x0003e;A, 1620T&#x0003e;C, 1672T&#x0003e;C, 1703G&#x0003e;T, 1710C&#x0003e;T, 1711T&#x0003e;G, 2296C&#x0003e;T, 2483G&#x0003e;A, 2994T&#x0003e;C, 4071delA, 4636A&#x0003e;C, 5668A, 6115C&#x0003e;T, 6586T&#x0003e;C, 6692C&#x0003e;G and 7160A&#x0003e;G which make amino acid changes in Phe118Leu, Arg128Leu and Ser131Ala (Mwenifumbo et al., 2008[<xref rid="R87" ref-type="bibr">87</xref>]). The <italic>in vivo</italic> and <italic>in vitro</italic> assays have proven that the final product is a loss-of-function enzyme (Ho et al., 2009[<xref rid="R49" ref-type="bibr">49</xref>]; Mwenifumbo et al., 2008[<xref rid="R87" ref-type="bibr">87</xref>]).</p><p><italic>CYP2A6*27</italic> has the following point mutations: -1301A&#x0003e;C, -1289G&#x0003e;A, -745A&#x0003e;G, 22C&#x0003e;T, 51G, 1620T&#x0003e;C, 1672T&#x0003e;C, 2162_2163GC&#x0003e;A, 2296C&#x0003e;T, 2483G&#x0003e;A, 2994T&#x0003e;C, 3872G&#x0003e;A, 4071delA, 4636A&#x0003e;C, 5668A, 5857T&#x0003e;A, 6586T&#x0003e;C, 6692C&#x0003e;G and 7160A&#x0003e;G, which makes the amino acid change Phe118Leu and also have a frameshift mutation, which displaces the frameshift to stop prematurely at 5<sup>th</sup> exon (Mwenifumbo et al., 2008[<xref rid="R87" ref-type="bibr">87</xref>]), resulting in a loss-of-function enzyme (Ho et al., 2009[<xref rid="R49" ref-type="bibr">49</xref>]; Mwenifumbo et al., 2008[<xref rid="R87" ref-type="bibr">87</xref>]).</p><p><italic>CYP2A6*28</italic> has two subvariants that share the following mutations: -1269T&#x0003e;C, 51G&#x0003e;A, 656G&#x0003e;T, 1620T&#x0003e;C, 4681T&#x0003e;G, 5668A, 5738C&#x0003e;T, 5745A&#x0003e;G, 5750G&#x0003e;C, 6354T&#x0003e;C, 6361C&#x0003e;A and 7160A&#x0003e;G, as well as a gene conversion in the 3'UTR of 58 bp. However, <italic>CYP2A6*28A </italic>also carries the point mutations 6385G&#x0003e;T, 6389C&#x0003e;G, 6390T&#x0003e;C and 6782C&#x0003e;G, on the other hand <italic>CYP2A6*28B</italic> has additionally the following mutations: 1381_1382CT&#x0003e;TC, 6960_6961ins GAAAAG and 1481_1486delCTCTCT. These mutations cause the amino acid change of Asn418Asp and Glu419Asp, however, the enzymatic activity is the same as the reference allele (Mwenifumbo et al., 2008[<xref rid="R87" ref-type="bibr">87</xref>]).</p><p>According to the HCAND<italic>, CYP2A6*29</italic>,<italic> 30</italic>,<italic> 32 </italic>and<italic> 33</italic> alleles are now in evaluation phase (&#x0201c;CYP2A6 allele nomenclature,&#x0201d; 2014[<xref rid="R25" ref-type="bibr">25</xref>]).</p><p><italic>CYP2A6*31</italic> has two subvariants which share the following mutations: -1289G&#x0003e;A, -1013A&#x0003e;G, -492_-470delCCCCTTCCTGAGACCCTTAACCCinsAATCCATATGTGGA ATCTG, 16A&#x0003e;C, 51G, 1339C&#x0003e;G, 1620T&#x0003e;C, 2721G&#x0003e;A, 2994T&#x0003e;C, 3255A&#x0003e;G, 3315C&#x0003e;T, 5668A, 6692C&#x0003e;G and 7160A&#x0003e;G. However, <italic>CYP2A6*31A</italic> also has the point mutation of 7568C&#x0003e;T and <italic>CYP2A6*31B</italic> the mutations in -975T&#x0003e;C, 467C&#x0003e;T and 4074delA that cause the amino acid change Met6Leu (Mwenifumbo et al., 2008[<xref rid="R87" ref-type="bibr">87</xref>]), but the enzymatic activity has not been evaluated.</p><p><italic>CYP2A6*34</italic> originated by the unequal crossover between <italic>CYP2A6 </italic>and<italic> CYP2A7,</italic> which resulted in a hybrid allele at the 5'UTR and exons 1- 4 belonging to <italic>CYP2A7 </italic>and from the 5<sup>th</sup> to 9<sup>th</sup> exon belonging to <italic>CYP2A6</italic> (di Iulio et al., 2009[<xref rid="R28" ref-type="bibr">28</xref>]). The enzymatic activity has not yet been evaluated, however could be similar to <italic>CYP2A6*12</italic> and it might be a loss-of-function allele.</p><p><italic>CYP2A6*35</italic> has two subvariants that share the following mutations: -1301A&#x0003e;C, -1289G&#x0003e;A, 1620T&#x0003e;C, 6458A&#x0003e;T, 6782C&#x0003e;G, 7160A&#x0003e;G and a gene conversion at the 3'UTR with <italic>CYP2A7</italic>. However, <italic>CYP2A6*35A</italic> also has the following point mutations: -1013A&#x0003e;G, 720G&#x0003e;A, 1137C&#x0003e;G, 2483G&#x0003e;A, 3225A&#x0003e;G, 6218A&#x0003e;G, 6282A&#x0003e;G, 6293T&#x0003e;C and 6354T&#x0003e;C; on the other hand, <italic>CYP2A6*35B</italic> has the following point mutations: -745A&#x0003e;G, 22C&#x0003e;T, 4084delA, 6835C&#x0003e;A and 6999T&#x0003e;C (Al Koudsi et al., 2010[<xref rid="R2" ref-type="bibr">2</xref>]). These mutations produce a protein that has the amino acid change Asn438Tyr which decrease the enzymatic activity according to <italic>in vitro</italic> and <italic>in vivo</italic> assays (Al Koudsi et al., 2010[<xref rid="R2" ref-type="bibr">2</xref>]).</p><p><italic>CYP2A6*36</italic> has the following point mutations: -1301A&#x0003e;C, -1289G&#x0003e;A, -745A&#x0003e;G, 22C&#x0003e;T, 1620T&#x0003e;C, 4084delA, 6458A&#x0003e;T, 6558T&#x0003e;C, gene conversion at 3'UTR, 6782C&#x0003e;G, 6835C&#x0003e;A, 6999T&#x0003e;C and 7160A&#x0003e;G that change the amino acid of Asn438Tyr and Ile471Thr (Al Koudsi et al., 2010[<xref rid="R2" ref-type="bibr">2</xref>]). To date there are no assays that prove their enzymatic activity.</p><p><italic>CYP2A6*37</italic> is produced by the following mutations: -1301A&#x0003e;C, -1289G&#x0003e;A, -745A&#x0003e;G, 22C&#x0003e;T, 1620T&#x0003e;C, 4084delA, 6354T&#x0003e;C, 6458A&#x0003e;T, 6558T&#x0003e;C, 6600G&#x0003e;T, 6782C&#x0003e;G, 6835C&#x0003e;A, 6936_6937insCACTT, 6961_6962insGAAAAG, 6989A&#x0003e;G, 6999T&#x0003e;C, 7160A&#x0003e;G and a gene conversion at the 3'UTR, which make the amino acid changes Asn438Tyr, Ile471Thr and Arg485Leu (Al Koudsi et al., 2010[<xref rid="R2" ref-type="bibr">2</xref>]). There are no assays that prove the enzymatic activity.</p><p><italic>CYP2A6*38</italic> is a result of the missense mutation 5023A&#x0003e;G, which produces the amino acid change of Tyr351His (Bloom et al., 2011[<xref rid="R17" ref-type="bibr">17</xref>]). An in silico assay classified the SNP as harmful, suggesting a decreased enzymatic activity (Bloom et al., 2011[<xref rid="R17" ref-type="bibr">17</xref>]).</p><p><italic>CYP2A6*39</italic> was described by Pilinguian et al. (2014[<xref rid="R109" ref-type="bibr">109</xref>]) as a missense mutation of 468G&#x0003e;A; however, the HCAND (&#x0201c;CYP2A6 allele nomenclature,&#x0201d; 2014[<xref rid="R25" ref-type="bibr">25</xref>]) adds the point mutations 171C&#x0003e;A, 1779G&#x0003e;A and 5717C&#x0003e;T, which cause the amino acid change Val68Met. The enzymatic activity of this allele is reported as decreased to half of the reference allele (Piliguian et al., 2014[<xref rid="R109" ref-type="bibr">109</xref>]).</p><p><italic>CYP2A6*40</italic> has the missense mutation 1767C&#x0003e;G (Piliguian et al., 2014[<xref rid="R109" ref-type="bibr">109</xref>]), but later the HCAND (&#x0201c;CYP2A6 allele nomenclature,&#x0201d; 2014[<xref rid="R25" ref-type="bibr">25</xref>]) added the point mutations 144G&#x0003e;A, 3492C&#x0003e;T and 5738C&#x0003e;T, which modifies the amino acid to Ile149Met. The enzymatic activity is reported to be half of the reference allele (Piliguian et al., 2014[<xref rid="R109" ref-type="bibr">109</xref>]).</p><p><italic>CYP2A6*41</italic> contains the missense mutation 3515G&#x0003e;A according to Pilinguian et al. (2014[<xref rid="R109" ref-type="bibr">109</xref>]), but the HCAND (&#x0201c;CYP2A6 allele nomenclature,&#x0201d; 2014[<xref rid="R25" ref-type="bibr">25</xref>]) added the point mutations 51G&#x0003e;A and 507C&#x0003e;T, which changed the amino acid to Arg265Gln. This allele was shown to have a minimal alteration in expression and a normal enzymatic activity (Piliguian et al., 2014[<xref rid="R109" ref-type="bibr">109</xref>]).</p><p><italic>CYP2A6*42</italic> is the result of a missense mutation 3524T&#x0003e;C according to Pilinguian et al. (2014[<xref rid="R109" ref-type="bibr">109</xref>]), but the HCAND (&#x0201c;CYP2A6 allele nomenclature,&#x0201d; 2014[<xref rid="R25" ref-type="bibr">25</xref>]) added the mutations 51G&#x0003e;A and 5684T&#x0003e;C, which made the amino acid change Ile268Thr that decreases the expression and enzymatic activity on <italic>in vivo</italic> and <italic>in vitro</italic> assays (Piliguian et al., 2014[<xref rid="R109" ref-type="bibr">109</xref>]).</p><p><italic>CYP2A6*43</italic> has the missense mutation 4406C&#x0003e;T, which makes the amino acid change to Thr303Ile and shows decreased expression and enzymatic activity in <italic>in vivo</italic> and <italic>in vitro</italic> assays (Piliguian et al., 2014[<xref rid="R109" ref-type="bibr">109</xref>]).</p><p><italic>CYP2A6*44</italic> carries the missense mutation 5661G&#x0003e;A according to Pilinguian et al. (2014[<xref rid="R109" ref-type="bibr">109</xref>]), but later the HCAND (&#x0201c;CYP2A6 allele nomenclature,&#x0201d; 2014[<xref rid="R25" ref-type="bibr">25</xref>]) added the mutations 51G&#x0003e;A, 5738C&#x0003e;T, 5745A&#x0003e;G and 5750G&#x0003e;C, which modify the amino acids to Glu390Lys, Asn418Asp and Glu419Asp. These mutations have been shown to reduce the enzymatic activity and the reference allele expression to one-third (Piliguian et al., 2014[<xref rid="R109" ref-type="bibr">109</xref>]).</p><p><italic>CYP2A6*45</italic> has a missense mutation at 6531T&#x0003e;C according to Pilinguian et al. (2014[<xref rid="R109" ref-type="bibr">109</xref>]), but later the HCAND (&#x0201c;CYP2A6 allele nomenclature,&#x0201d; 2014[<xref rid="R25" ref-type="bibr">25</xref>]) added the point mutations 51G&#x0003e;A and 4464G&#x0003e;A, which change the amino acid Leu462Pro. The mutations have been proven (as in <italic>CYP2A6*44</italic>) to reduce the enzymatic activity and the reference allele expression to one-third (Piliguian et al., 2014[<xref rid="R109" ref-type="bibr">109</xref>]).</p><p>There are two <italic>CYP2A6</italic> gene duplications: <italic>CYP2A6*1X2A</italic> originated by an unequal crossover from the 8<sup>th</sup> to 9<sup>th</sup> exon with <italic>CYP2A6*4D</italic> as a reciprocal product (Rao et al., 2000[<xref rid="R112" ref-type="bibr">112</xref>]). <italic>CYP2A6*1X2B</italic> also originated by an unequal crossover of <italic>CYP2A7</italic> from 5.2 to 5.6 kb downstream of the stop codon with <italic>CYP2A6*4B</italic> as the reciprocal product (Fukami et al., 2007[<xref rid="R40" ref-type="bibr">40</xref>]). Its enzyme activity has been shown to increase in <italic>in vivo</italic> assays (Rao et al., 2000[<xref rid="R112" ref-type="bibr">112</xref>]).</p><p><italic>CYP2A6</italic> has been suggested as a highly polymorphic gene because it is located in a small chromosomal region that contains several genes and some unequal crossover events, point mutations and genetic conversions between <italic>CYP2A6</italic> and<italic> CYP2A7</italic> (Hoffman et al., 1995[<xref rid="R51" ref-type="bibr">51</xref>]). These facts, plus evolutionary forces such as genetic drift and natural selection, may have resulted in this genetic variability, which spread among human populations (Ingelman-Sundberg, 2004[<xref rid="R56" ref-type="bibr">56</xref>], 2005[<xref rid="R58" ref-type="bibr">58</xref>]). This genetic variability, similar to other CYP450 genes, could explain the metabolic response to exogenous compounds such as nicotine and other drugs that ranges from 20-40 % (Ingelman-Sundberg, 2001[<xref rid="R57" ref-type="bibr">57</xref>]).</p><p><italic>CYP2A6</italic> genotypes can be classified according to their alleles and their enzymatic activity, which is referred to as the metabolism range of 3-hydroxycotinine/cotinine (Dempsey et al., 2004[<xref rid="R27" ref-type="bibr">27</xref>]), as mentioned below:</p><p>-Ultrarapid metabolizers. Individuals who have an enzymatic activity &#x0003e;100 % of normal; they contain more than two functional alleles (the <italic>CYP2A6</italic>*1X2 allele).</p><p>-Normal metabolizers. Individuals who have an enzymatic activity of 100 % (normal); they contain two functional alleles.</p><p>-Intermediate metabolizers. Individuals who have an enzymatic activity &#x02264;75 % of normal may contain a functional and a defective allele or even two partially defective alleles.</p><p>-Slow metabolizers. Individuals who have an enzymatic activity &#x02264;50 % of normal can contain a functional and a loss-of-function allele or even two loss-of-function alleles.</p></sec><sec><title>Effects of CYP2A6 Genetic Variants on Tobacco Consumption</title><p>The genetic variability of CYP2A6 directly influences the range of nicotine metabolism in the body, which can indirectly affect the reinforcing and aversive nicotine properties in the brain and can change the individual risk of nicotine dependence. To prove the effect of <italic>CYP2A6 </italic>variants on tobacco consumption, several studies were conducted that included family, twin and non-related subject designs. These studies associate an allele with the amount of metabolized nicotine or another variable related to tobacco consumption.</p><p>Smokers who carry some <italic>CYP2A6</italic> alleles show a different smoking behavior compared to carrying the wild-type allele, suggesting that smokers regulate their smoking behavior to obtain the desired nicotine levels in their body (Malaiyandi et al., 2005[<xref rid="R82" ref-type="bibr">82</xref>]; Rao et al., 2000[<xref rid="R112" ref-type="bibr">112</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]).</p><p>The importance of the null and decreased biological function alleles is explained in smokers (carrying these alleles) who exhibit less time smoking (Liu et al., 2011[<xref rid="R74" ref-type="bibr">74</xref>]; Malaiyandi et al., 2006[<xref rid="R81" ref-type="bibr">81</xref>]), fewer cigarettes smoked (Audrain-McGovern et al., 2007[<xref rid="R9" ref-type="bibr">9</xref>]; Fujieda et al., 2004[<xref rid="R36" ref-type="bibr">36</xref>]; Malaiyandi et al., 2005[<xref rid="R82" ref-type="bibr">82</xref>]; Minematsu et al., 2006[<xref rid="R84" ref-type="bibr">84</xref>]; O'Loughlin et al., 2004[<xref rid="R99" ref-type="bibr">99</xref>]; Pan et al., 2015[<xref rid="R104" ref-type="bibr">104</xref>]; Rao et al., 2000[<xref rid="R112" ref-type="bibr">112</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]; Thorgeirsson et al., 2010[<xref rid="R132" ref-type="bibr">132</xref>]), fewer aspirations per cigarette (Strasser et al., 2011[<xref rid="R125" ref-type="bibr">125</xref>]), later smoking onset (Gu et al., 2000[<xref rid="R43" ref-type="bibr">43</xref>]; O'Loughlin et al., 2004[<xref rid="R99" ref-type="bibr">99</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]) and less nicotine dependence (Wassenaar et al., 2011[<xref rid="R144" ref-type="bibr">144</xref>]). Likewise, it has been reported that these individuals respond better to replacement nicotine therapy (Lerman et al., 2010[<xref rid="R72" ref-type="bibr">72</xref>]; Malaiyandi et al., 2006[<xref rid="R81" ref-type="bibr">81</xref>]). Moreover, they tolerate withdrawal symptoms (Kubota et al., 2006[<xref rid="R68" ref-type="bibr">68</xref>]) better and have higher rates of quitting smoking spontaneously (Chenoweth et al., 2013[<xref rid="R21" ref-type="bibr">21</xref>]; Malaiyandi et al., 2006[<xref rid="R81" ref-type="bibr">81</xref>]; Minematsu et al., 2003[<xref rid="R85" ref-type="bibr">85</xref>]; Ray et al., 2009[<xref rid="R113" ref-type="bibr">113</xref>]). These alleles have also been associated with lung, bladder, nasopharyngeal, esophageal and oral cancer (Fujieda et al., 2004[<xref rid="R36" ref-type="bibr">36</xref>]; Hosono et al., 2015[<xref rid="R53" ref-type="bibr">53</xref>]; Islam et al., 2013[<xref rid="R59" ref-type="bibr">59</xref>]; Ito et al., 2015[<xref rid="R60" ref-type="bibr">60</xref>]; Kumondai et al., 2016[<xref rid="R69" ref-type="bibr">69</xref>]; Lourembam et al., 2015[<xref rid="R77" ref-type="bibr">77</xref>]; Miyamoto et al., 1999[<xref rid="R86" ref-type="bibr">86</xref>]; Song et al., 2009[<xref rid="R123" ref-type="bibr">123</xref>]; Tamaki et al., 2011[<xref rid="R130" ref-type="bibr">130</xref>]; Tan et al., 2001[<xref rid="R131" ref-type="bibr">131</xref>]; Tiwawech et al., 2006[<xref rid="R136" ref-type="bibr">136</xref>]; Topcu et al., 2002[<xref rid="R137" ref-type="bibr">137</xref>]; Wassenaar et al., 2015[<xref rid="R145" ref-type="bibr">145</xref>]).</p><p>On the other hand, some reports do not prove the association between null and decreased <italic>CYP2A6</italic> alleles related to tobacco consumption (London et al., 1999[<xref rid="R75" ref-type="bibr">75</xref>]; Loriot et al., 2001[<xref rid="R76" ref-type="bibr">76</xref>]; Sabol and Hamer, 1999[<xref rid="R116" ref-type="bibr">116</xref>]; Schulz et al., 2001[<xref rid="R118" ref-type="bibr">118</xref>]; Tiihonen et al., 2000[<xref rid="R133" ref-type="bibr">133</xref>]; Zhang et al., 2001[<xref rid="R153" ref-type="bibr">153</xref>]). This lack of association may occur because of several factors such as designing the population stratification (comparing populations where there are substructures between cases and controls) and population ethnicity, lack of detailed phenotypic evaluation, indeterminate comorbidities, different genotyping methods, examination of different allelic variants, inconsistency in smoking history and differences in symptoms of nicotine dependence among smokers (Lerman and Niaura, 2002[<xref rid="R73" ref-type="bibr">73</xref>]; O'Loughlin et al., 2004[<xref rid="R99" ref-type="bibr">99</xref>]).</p><p>Detecting the alleles of <italic>CYP2A6 </italic>can allow us to characterize different smoking behaviors and smoking-related diseases among individuals (Fujieda et al., 2004[<xref rid="R36" ref-type="bibr">36</xref>]), due to their role in nicotine metabolism and the metabolism of certain carcinogenic compounds. This could have an implication on public health by reducing the harmful effects related to smoking and developing a personalized smoking cessation according to their individual genotype (Liu et al., 2011[<xref rid="R74" ref-type="bibr">74</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]). However, these alleles have a specific distribution in worldwide populations.</p></sec><sec><title>Population Distribution of CYP2A6 Alleles</title><p>The <italic>CYP2A6</italic> allele distribution has an interethnic pattern. Knowing the individual differences in nicotine metabolism may allow us to answer the following questions: Why do some people become regular smokers after initial exposure, while others experience negative reactions and discontinue use? Why do some people smoke in greater quantities than others? Why do different individuals not respond the same way to drug therapies to quit smoking? Why do some individuals develop smoking related diseases faster than others? (O'Loughlin et al., 2004[<xref rid="R99" ref-type="bibr">99</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]; Swan et al, 1997[<xref rid="R128" ref-type="bibr">128</xref>], 2005[<xref rid="R127" ref-type="bibr">127</xref>]).</p><p>Therefore, we present the allele frequencies in reported populations where tobacco consumption, cancer and nicotine metabolism were studied and in cohorts and general population studies, which involve <italic>CYP2A6</italic>. The number of reports of each allele according to a population group is summarized in Figure 2<xref ref-type="fig" rid="F2">(Fig. 2)</xref>. For more practical reasons, we only showed the frequency without distinction for alleles with subvariants, except for the wild-type allele <italic>CYP2A6</italic>*1 whose frequency was not completely calculated because some studies assign an unidentified genotype to the reference allele.</p><p>The wild-type allele subvariants are distributed in a particular way on worldwide populations. <italic>CYP2A6*1A</italic> is found in almost all populations studied such as Caucasian populations (Spanish, British, French, Swedish and Serbian), which range from 57-67 % (Djordjevic et al., 2010[<xref rid="R30" ref-type="bibr">30</xref>], 2013[<xref rid="R31" ref-type="bibr">31</xref>]; Gambier et al., 2005[<xref rid="R42" ref-type="bibr">42</xref>]; Huang et al., 2005[<xref rid="R54" ref-type="bibr">54</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>], 2004[<xref rid="R95" ref-type="bibr">95</xref>]; Oscarson, et al., 1999[<xref rid="R102" ref-type="bibr">102</xref>]; Soriano et al., 2011[<xref rid="R124" ref-type="bibr">124</xref>]), Africans, and Ethiopians, which reported an allele frequency of 34.8 % (Aklillu et al., 2014[<xref rid="R1" ref-type="bibr">1</xref>]). However, in African Americans, Ghanaians and Namibians the frequencies were between 66.5-80.5 % (Gyamfi et al., 2005[<xref rid="R45" ref-type="bibr">45</xref>]; Nakajima et al., 2004[<xref rid="R95" ref-type="bibr">95</xref>]; Takeshita et al., 2006[<xref rid="R129" ref-type="bibr">129</xref>]) while it was the opposite in Asians. Asians living in the UK report a frequency of 64.1 % while East and South Asian populations (Chinese, Japanese, Korean, Malaysian, Thai, Indian, Bangladeshi and Sri Lankan) report a frequency of 27-52 % (Ariyoshi et al., 2002[<xref rid="R6" ref-type="bibr">6</xref>]; Djordjevic et al., 2013[<xref rid="R31" ref-type="bibr">31</xref>]; Islam et al., 2013[<xref rid="R59" ref-type="bibr">59</xref>]; Ito et al., 2015[<xref rid="R60" ref-type="bibr">60</xref>]; Iwahashi et al., 2004[<xref rid="R61" ref-type="bibr">61</xref>]; Kwon et al., 2001[<xref rid="R70" ref-type="bibr">70</xref>]; Mahavorasirikul et al., 2009[<xref rid="R79" ref-type="bibr">79</xref>]; Nakajima et al., 2001[<xref rid="R92" ref-type="bibr">92</xref>], 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Nurfadhlina et al., 2006[<xref rid="R98" ref-type="bibr">98</xref>]; Oscarson et al., 1999[<xref rid="R102" ref-type="bibr">102</xref>]; Peamkrasatam et al., 2006[<xref rid="R107" ref-type="bibr">107</xref>]; Takeshita et al., 2006[<xref rid="R129" ref-type="bibr">129</xref>]; Topcu et al., 2002[<xref rid="R137" ref-type="bibr">137</xref>]; Yoshida et al., 2002[<xref rid="R150" ref-type="bibr">150</xref>]). In the Middle East, the Turkish report a frequency of 23.9-69.7 % (Takeshita et al., 2006[<xref rid="R129" ref-type="bibr">129</xref>]; von Richter et al. (2004[<xref rid="R142" ref-type="bibr">142</xref>]). The American mestizo populations such as Brazilian and Ecuadorian show a frequency of 71.7 % (Rossini et al., 2006[<xref rid="R115" ref-type="bibr">115</xref>]) and 61.7 % (Soriano et al., 2011[<xref rid="R124" ref-type="bibr">124</xref>]), respectively. <italic>CYP2A6*1B</italic> frequency is higher in East and South Asian populations and is reported as 26.7-54.2 % (Ariyoshi et al., 2002[<xref rid="R6" ref-type="bibr">6</xref>]; Djordjevic et al., 2013[<xref rid="R31" ref-type="bibr">31</xref>]; Islam et al., 2013[<xref rid="R59" ref-type="bibr">59</xref>]; Ito et al., 2015[<xref rid="R60" ref-type="bibr">60</xref>]; Iwahashi et al., 2004[<xref rid="R61" ref-type="bibr">61</xref>]; Kwon et al., 2001[<xref rid="R70" ref-type="bibr">70</xref>]; Lourembam et al., 2015[<xref rid="R77" ref-type="bibr">77</xref>]; Mahavorasirikul et al., 2009[<xref rid="R79" ref-type="bibr">79</xref>]; Nakajima et al., 2001[<xref rid="R92" ref-type="bibr">92</xref>], 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Nurfadhlina et al., 2006[<xref rid="R98" ref-type="bibr">98</xref>]; Oscarson et al., 1999[<xref rid="R102" ref-type="bibr">102</xref>]; Peamkrasatam et al., 2006[<xref rid="R107" ref-type="bibr">107</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]; Takeshita et al., 2006[<xref rid="R129" ref-type="bibr">129</xref>]; Tiwawech et al., 2006[<xref rid="R136" ref-type="bibr">136</xref>]; Topcu et al., 2002[<xref rid="R137" ref-type="bibr">137</xref>]; Yoshida et al., 2002[<xref rid="R150" ref-type="bibr">150</xref>]; Yusof and Gan, 2009[<xref rid="R152" ref-type="bibr">152</xref>]). In Caucasians (Nonspecific, North American, Spanish, British, French, Swedish and Serbian) a frequency of 27.6-33.5 % (Bloom et al., 2011[<xref rid="R17" ref-type="bibr">17</xref>]; Djordjevic et al., 2013[<xref rid="R31" ref-type="bibr">31</xref>], 2010[<xref rid="R30" ref-type="bibr">30</xref>]; Gambier et al., 2005[<xref rid="R42" ref-type="bibr">42</xref>]; Haberl et al., 2005[<xref rid="R46" ref-type="bibr">46</xref>]; Huang et al., 2005[<xref rid="R54" ref-type="bibr">54</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>], 2004[<xref rid="R95" ref-type="bibr">95</xref>]; Oscarson et al., 1999[<xref rid="R102" ref-type="bibr">102</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]; Soriano et al., 2011[<xref rid="R124" ref-type="bibr">124</xref>]) is reported, but it is lower in Turkish populations (25.9-26.7 % (Takeshita et al., 2006[<xref rid="R129" ref-type="bibr">129</xref>]; von Richter et al., 2004[<xref rid="R142" ref-type="bibr">142</xref>])). African populations such as African American, Ghanaian and Namibian show lower frequencies (11.2-19.8 % (Gyamfi et al., 2005[<xref rid="R45" ref-type="bibr">45</xref>]; Ho et al., 2009[<xref rid="R49" ref-type="bibr">49</xref>]; Mwenifumbo et al., 2008[<xref rid="R87" ref-type="bibr">87</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>], 2004[<xref rid="R95" ref-type="bibr">95</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]; Takeshita et al., 2006[<xref rid="R129" ref-type="bibr">129</xref>])), except for Ethiopian populations (31.3 % (Aklillu et al., 2014[<xref rid="R1" ref-type="bibr">1</xref>])). American mestizo populations (Brazilian and Ecuadorian) have a frequency of 26.4-31.2 % (Rossini et al., 2006[<xref rid="R115" ref-type="bibr">115</xref>]; Soriano et al., 2011[<xref rid="R124" ref-type="bibr">124</xref>]; Vasconcelos et al., 2005[<xref rid="R139" ref-type="bibr">139</xref>]) while the Native Canadian and Alaskan Yupik show a frequency of 55-65.3 % (Rossini et al., 2006[<xref rid="R115" ref-type="bibr">115</xref>]; Soriano et al., 2011[<xref rid="R124" ref-type="bibr">124</xref>]; Vasconcelos et al., 2005[<xref rid="R139" ref-type="bibr">139</xref>]). <italic>CYP2A6*1D</italic> showed a higher frequency in the African nonspecific population (&#x0003e;50 % (Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>])) than in the Ethiopian population (29.4 %) (Aklillu et al., 2014[<xref rid="R1" ref-type="bibr">1</xref>]). In the Caucasian population (Nonspecific, North American and Swedish) the frequency is 26.7-40 % (Bloom et al., 2011[<xref rid="R17" ref-type="bibr">17</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]; von Richter et al., 2004[<xref rid="R142" ref-type="bibr">142</xref>]) and in Turkish populations it is 32.3 % (von Richter et al., 2004[<xref rid="R142" ref-type="bibr">142</xref>]). Asian populations (Japanese and Korean) show a frequency of 10-20 % (Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]). <italic>CYP2A6*1F</italic> has been reported only in nonspecific Caucasian (1.8 % (Nakajima et al., 2004[<xref rid="R95" ref-type="bibr">95</xref>])) and Turkish (2.2 % (Takeshita et al., 2006[<xref rid="R129" ref-type="bibr">129</xref>])) populations, but was not found in African and Japanese populations (Nakajima et al., 2004[<xref rid="R95" ref-type="bibr">95</xref>]; Takeshita et al., 2006[<xref rid="R129" ref-type="bibr">129</xref>]). <italic>CYP2A6*1G</italic> has a higher frequency in African populations (North American and Namibian) (12.3-13.3 % (Nakajima et al., 2004[<xref rid="R95" ref-type="bibr">95</xref>]; Takeshita et al., 2006[<xref rid="R129" ref-type="bibr">129</xref>])) than in Caucasian populations (1.2 % (Nakajima et al., 2004[<xref rid="R95" ref-type="bibr">95</xref>])), but it was not reported in Turkish and Japanese populations (Takeshita et al., 2006[<xref rid="R129" ref-type="bibr">129</xref>]). <italic>CYP2A6*1H</italic> has been found higher in Caucasian populations such as nonspecific Caucasian (&#x0003e;11 % (Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>])), North American (7.9 % (Bloom et al., 2011[<xref rid="R17" ref-type="bibr">17</xref>])) and Swedish (3.1 % (von Richter et al., 2004[<xref rid="R142" ref-type="bibr">142</xref>])), followed by nonspecific African (9.8 % (Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>])), Turkish (5.2 % (von Richter et al., 2004[<xref rid="R142" ref-type="bibr">142</xref>])), Japanese (4.5 % (Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>])) and Korean (1.6 % (Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>])). <italic>CYP2A6*1J</italic> has been reported as non-existent in Caucasian, African, Japanese and Korean populations (Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]).</p><p><italic>CYP2A6</italic>*2 has a higher frequency in Caucasian populations such as nonspecific Caucasian (1.1-5.3 % (Audrain-McGovern et al., 2007[<xref rid="R9" ref-type="bibr">9</xref>]; Benowitz et al., 2006[<xref rid="R13" ref-type="bibr">13</xref>]; Haberl et al., 2005[<xref rid="R46" ref-type="bibr">46</xref>]; Malaiyandi et al., 2006[<xref rid="R80" ref-type="bibr">80</xref>][<xref rid="R81" ref-type="bibr">81</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>], 2004[<xref rid="R95" ref-type="bibr">95</xref>]; Paschke et al., 2001[<xref rid="R106" ref-type="bibr">106</xref>]; Rao et al., 2000[<xref rid="R112" ref-type="bibr">112</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]; Xu et al., 2002[<xref rid="R147" ref-type="bibr">147</xref>])), English populations such as British (2.5 % (Huang et al., 2005[<xref rid="R54" ref-type="bibr">54</xref>])) and Canadian (3.4 % (O'Loughlin et al., 2004[<xref rid="R99" ref-type="bibr">99</xref>])); and in Central Europe populations such as German, French and Spanish it has been reported from 2.3-3 % (Bourian et al., 2000[<xref rid="R19" ref-type="bibr">19</xref>]; Loriot et al., 2001[<xref rid="R76" ref-type="bibr">76</xref>]; Oscarson, et al., 1999[<xref rid="R103" ref-type="bibr">103</xref>])). In North of Europe populations such as Finish and Swedish, a frequency of 1.1-3 % (Oscarson et al., 1998[<xref rid="R100" ref-type="bibr">100</xref>], 1999[<xref rid="R103" ref-type="bibr">103</xref>]) was reported. In African populations (Afro American and Ethiopian), the frequency is less than 1 % (Malaiyandi et al., 2005[<xref rid="R82" ref-type="bibr">82</xref>]; Nakajima et al., 2006[<xref rid="R95" ref-type="bibr">95</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]) and is not reported in Ghanaian populations (Gyamfi et al., 2005[<xref rid="R45" ref-type="bibr">45</xref>]). The frequency is different in American populations: Amerindian populations, Canadian natives and Alaskan Yupik have a frequency less than 1 % (Binnington et al., 2012[<xref rid="R16" ref-type="bibr">16</xref>]; Nowak et al., 1998[<xref rid="R96" ref-type="bibr">96</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]). However, the mestizo populations such as Brazilian (1.6-1.7 %) (Rossini et al., 2006[<xref rid="R115" ref-type="bibr">115</xref>]; Vasconcelos et al., 2005[<xref rid="R139" ref-type="bibr">139</xref>]) and Chilean (2-3.7 %) (C&#x000e1;ceres et al., 2012[<xref rid="R20" ref-type="bibr">20</xref>]; Roco et al., 2012[<xref rid="R114" ref-type="bibr">114</xref>]) show a frequency higher than Hispanics (Benowitz et al., 2006[<xref rid="R13" ref-type="bibr">13</xref>]). In East and Southeast Asian populations such as Chinese, Korean, Japanese, Malaysian and Thai, <italic>CYP2A6</italic>*2 is non-existent (Huang et al., 2005[<xref rid="R54" ref-type="bibr">54</xref>]; Kitagawa et al., 1999[<xref rid="R62" ref-type="bibr">62</xref>]; Malaiyandi et al., 2005[<xref rid="R82" ref-type="bibr">82</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Nurfadhlina et al., 2006[<xref rid="R98" ref-type="bibr">98</xref>]; Oscarson et al., 1999[<xref rid="R103" ref-type="bibr">103</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]). A minimum range of 1 % (Nurfadhlina et al., 2006[<xref rid="R98" ref-type="bibr">98</xref>]) was reported in Indians. The Iranian population had a frequency higher than 2.2 % (Emamghoreishi et al., 2008[<xref rid="R32" ref-type="bibr">32</xref>]; Heravi et al., 2010[<xref rid="R48" ref-type="bibr">48</xref>]), unlike the Turkish population where <italic>CYP2A6</italic>*2 was not found (Cok et al., 2001[<xref rid="R23" ref-type="bibr">23</xref>]).</p><p>The methodologies for the detection, function and allelic frequency of <italic>CYP2A6*</italic>3 have been controversial (Fernandez-Salguero et al., 1995[<xref rid="R34" ref-type="bibr">34</xref>]; Oscarson et al., 1998[<xref rid="R100" ref-type="bibr">100</xref>]; Yamano et al., 1990[<xref rid="R148" ref-type="bibr">148</xref>]); however, we present the reported frequency. The highest frequency (13.8 % (Nowak et al., 1998[<xref rid="R96" ref-type="bibr">96</xref>])) was reported in Canadian natives, followed by Turkish (12 % (Cok et al., 2001[<xref rid="R23" ref-type="bibr">23</xref>])), German (1.4 %) (Bourian et al., 2000[<xref rid="R19" ref-type="bibr">19</xref>]) and Indian (1.1 %) (Nurfadhlina et al., 2006[<xref rid="R98" ref-type="bibr">98</xref>]) populations. However, in African (Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Paschke et al., 2001[<xref rid="R106" ref-type="bibr">106</xref>]). Caucasian (Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Paschke et al., 2001[<xref rid="R106" ref-type="bibr">106</xref>]), Spanish (Oscarson et al., 1999[<xref rid="R102" ref-type="bibr">102</xref>]), Chilean (C&#x000e1;ceres et al., 2012[<xref rid="R20" ref-type="bibr">20</xref>]), Iranian (Heravi et al., 2010[<xref rid="R48" ref-type="bibr">48</xref>]), Korean (Kwon et al., 2001[<xref rid="R70" ref-type="bibr">70</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Yoshida et al., 2002[<xref rid="R150" ref-type="bibr">150</xref>]), Chinese (Nurfadhlina et al., 2006[<xref rid="R98" ref-type="bibr">98</xref>]; Oscarson et al., 1999[<xref rid="R103" ref-type="bibr">103</xref>]), Malaysian (Nurfadhlina et al., 2006[<xref rid="R98" ref-type="bibr">98</xref>]) and Japanese (Nakajima et al., 2001[<xref rid="R92" ref-type="bibr">92</xref>], 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Yoshida et al., 2002[<xref rid="R150" ref-type="bibr">150</xref>]) (except a report of 0.2 % (Minematsu et al., 2003[<xref rid="R85" ref-type="bibr">85</xref>])) populations, this allele was not found. </p><p><italic>CYP2A6*</italic>4 may be the most widely studied allele in all populations. East Asian populations such as Japanese (11.2-25.6 % (Ariyoshi et al., 2002[<xref rid="R6" ref-type="bibr">6</xref>]; Fujieda et al., 2004[<xref rid="R36" ref-type="bibr">36</xref>]; Fukami et al., 2006[<xref rid="R39" ref-type="bibr">39</xref>]; Ito et al., 2015[<xref rid="R60" ref-type="bibr">60</xref>]; Iwahashi et al., 2004[<xref rid="R61" ref-type="bibr">61</xref>]; Minematsu et al., 2003[<xref rid="R85" ref-type="bibr">85</xref>], 2006[<xref rid="R84" ref-type="bibr">84</xref>]; Nakajima et al., 2001[<xref rid="R92" ref-type="bibr">92</xref>], 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]; Takeshita et al., 2006[<xref rid="R129" ref-type="bibr">129</xref>]; Tamaki et al., 2011[<xref rid="R130" ref-type="bibr">130</xref>]; Xu et al., 2002[<xref rid="R147" ref-type="bibr">147</xref>]; Yoshida et al., 2002[<xref rid="R150" ref-type="bibr">150</xref>])), Chinese (4.9-14 % (Gu et al, 2005[<xref rid="R44" ref-type="bibr">44</xref>]; Liu et al., 2011[<xref rid="R74" ref-type="bibr">74</xref>]; Nurfadhlina et al., 2006[<xref rid="R98" ref-type="bibr">98</xref>]; Oscarson et al., 1999[<xref rid="R102" ref-type="bibr">102</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]; Song et al., 2009[<xref rid="R123" ref-type="bibr">123</xref>]; Tan et al., 2001[<xref rid="R131" ref-type="bibr">131</xref>]; Xu et al., 2002[<xref rid="R147" ref-type="bibr">147</xref>]; Yuan et al., 2016[<xref rid="R151" ref-type="bibr">151</xref>])), Korean (9.4-11 %) (Djordjevic et al., 2013[<xref rid="R31" ref-type="bibr">31</xref>]; Fukami et al., 2006[<xref rid="R39" ref-type="bibr">39</xref>]; Kwon et al., 2001[<xref rid="R70" ref-type="bibr">70</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Yoshida et al., 2002[<xref rid="R150" ref-type="bibr">150</xref>]), Thai (4-14.2 % (Mahavorasirikul et al., 2009[<xref rid="R79" ref-type="bibr">79</xref>]; Peamkrasatam et al., 2006[<xref rid="R107" ref-type="bibr">107</xref>]; Tiwawech et al., 2006[<xref rid="R136" ref-type="bibr">136</xref>])), Malaysian (7-16.7 % (Nurfadhlina et al., 2006[<xref rid="R98" ref-type="bibr">98</xref>]; Yusof and Gan, 2009[<xref rid="R152" ref-type="bibr">152</xref>])) and Vietnamese (11.8 % (Veiga et al., 2009[<xref rid="R140" ref-type="bibr">140</xref>])) showed the highest frequency among populations. However, some Asian populations that reside in a foreign country such as those living in the UK report a frequency of less than 1 % (Benowitz et al., 2006[<xref rid="R13" ref-type="bibr">13</xref>]; Huang et al., 2005[<xref rid="R54" ref-type="bibr">54</xref>]). However, ethnic populations in Asian countries show no differences in the frequencies such as in Japan with the Shimane (18.2 %), Tottori (16.9 %), Fukoka (20.6 %) and Ehime (25.9 % (Takeshita et al., 2006[<xref rid="R129" ref-type="bibr">129</xref>]) and in China with the Han (7.9 %), Uighur (15 %), Bouyei (0 %) and Tibetan (2 %) (Pang et al., 2015[<xref rid="R105" ref-type="bibr">105</xref>]). South Asian populations such as Bangladeshi (4.7-11.2 % (Islam et al., 2013[<xref rid="R59" ref-type="bibr">59</xref>])), Sri Lankan (2.8-9.6 % (Topcu et al., 2002[<xref rid="R137" ref-type="bibr">137</xref>])) and Indian (1.5-8.9 % (Krishnakumar et al., 2012[<xref rid="R67" ref-type="bibr">67</xref>]; Nurfadhlina et al., 2006[<xref rid="R98" ref-type="bibr">98</xref>]) show a high frequency. Middle East populations such as Turkish (2.2 % (Takeshita et al., 2006[<xref rid="R129" ref-type="bibr">129</xref>])) and Iranian (0.9-2.5 % (Emamghoreishi et al., 2008[<xref rid="R32" ref-type="bibr">32</xref>]; Heravi et al., 2010[<xref rid="R48" ref-type="bibr">48</xref>])) show a lower frequency. However, the distribution is different in Caucasian populations: Nonspecific Caucasians had a frequency lower than 3 % (Audrain-McGovern et al., 2007[<xref rid="R9" ref-type="bibr">9</xref>]; Benowitz et al., 2006[<xref rid="R13" ref-type="bibr">13</xref>]; Fukami et al., 2006[<xref rid="R39" ref-type="bibr">39</xref>]; Malaiyandi et al., 2006[<xref rid="R80" ref-type="bibr">80</xref>][<xref rid="R81" ref-type="bibr">81</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>], 2004[<xref rid="R95" ref-type="bibr">95</xref>]; Rao et al., 2000[<xref rid="R112" ref-type="bibr">112</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]; Xu et al., 2002[<xref rid="R147" ref-type="bibr">147</xref>]); Atlantic Europe populations such as Spanish (0.5-4 % (Oscarson et al., 1999[<xref rid="R103" ref-type="bibr">103</xref>]; Soriano et al., 2011[<xref rid="R124" ref-type="bibr">124</xref>])) and French (3.8 % (Gambier et al., 2005[<xref rid="R42" ref-type="bibr">42</xref>])) also have this allele; English populations such as British (0.3 % (Huang et al., 2005[<xref rid="R54" ref-type="bibr">54</xref>])), North American (1.6 % (Bloom et al., 2011[<xref rid="R17" ref-type="bibr">17</xref>])) and Canadian (0.2 % (O'Loughlin et al., 2004[<xref rid="R99" ref-type="bibr">99</xref>])) had a lower frequency; North of Europe populations such as Finish (1 % (Oscarson et al., 1999[<xref rid="R103" ref-type="bibr">103</xref>])) and Swedish (1.1 % (Djordjevic et al., 2013[<xref rid="R31" ref-type="bibr">31</xref>])) also report this allele. Southeastern Europe populations such as Serbian report a frequency of 2.9 % (Djordjevic et al., 2010[<xref rid="R30" ref-type="bibr">30</xref>]) and Tatar from Russia reported a frequency range from 6.8-16.9 % (Korytina et al., 2014[<xref rid="R66" ref-type="bibr">66</xref>]). African populations had a frequency less than 2 % and are reported as follows: Nonspecific African (&#x02264;1.9 % (Ho et al., 2009[<xref rid="R49" ref-type="bibr">49</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>])), African American (0.5-0.6 % (Fukami et al., 2006[<xref rid="R39" ref-type="bibr">39</xref>]; Nakajima et al., 2004[<xref rid="R95" ref-type="bibr">95</xref>])), Ghanaian (2 % (Gyamfi et al., 2005[<xref rid="R45" ref-type="bibr">45</xref>])), Ethiopian (0.6 % (Aklillu et al., 2014[<xref rid="R1" ref-type="bibr">1</xref>])) and Namibian (0 % (Takeshita et al., 2006[<xref rid="R129" ref-type="bibr">129</xref>])). American populations show a variable frequency: Amerindian populations as Alaskan Yupik (14.5 % (Binnington et al., 2012[<xref rid="R16" ref-type="bibr">16</xref>])) have a higher frequency than Canadian natives (1 % (Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>])) and more than mestizo populations as Brazilian (0.5 % (Vasconcelos et al., 2005[<xref rid="R139" ref-type="bibr">139</xref>])), Ecuadorian (7.1 % (Soriano et al., 2011[<xref rid="R124" ref-type="bibr">124</xref>])), Chilean (3.7-4 % (C&#x000e1;ceres et al., 2012[<xref rid="R20" ref-type="bibr">20</xref>]; Roco et al., 2012[<xref rid="R114" ref-type="bibr">114</xref>])) and Hispanics (0 % (Benowitz et al., 2006[<xref rid="R13" ref-type="bibr">13</xref>])). On the other side of the world, the M&#x00101;ori native population from New Zealand report a high frequency (9.6 % (Lea et al., 2008[<xref rid="R71" ref-type="bibr">71</xref>])) of this allele and it is the only population reported in Oceania.</p><p><italic>CYP2A6</italic>*5 is found in a higher frequency in Asian populations, East and Southeast Asian populations such as the Vietnamese had the highest frequency (14.6 % (Veiga et al., 2009[<xref rid="R140" ref-type="bibr">140</xref>])) compared with the Chinese (Liu et al., 2011[<xref rid="R74" ref-type="bibr">74</xref>]; Nurfadhlina et al., 2006[<xref rid="R98" ref-type="bibr">98</xref>]; Oscarson et al., 1999[<xref rid="R103" ref-type="bibr">103</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]), Korean (Djordjevic et al., 2013[<xref rid="R31" ref-type="bibr">31</xref>]; Kwon et al., 2001[<xref rid="R70" ref-type="bibr">70</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Yoshida et al., 2002[<xref rid="R150" ref-type="bibr">150</xref>]) and Malaysian (Nurfadhlina et al., 2006[<xref rid="R98" ref-type="bibr">98</xref>]) populations with a frequency less than 1.5 %. However, this allele is not found in the Japanese (Nakajima et al., 2001[<xref rid="R92" ref-type="bibr">92</xref>], 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]; Yoshida et al., 2002[<xref rid="R150" ref-type="bibr">150</xref>]); South Asians such as Indians show a frequency of less than 1 % (Krishnakumar et al., 2012[<xref rid="R67" ref-type="bibr">67</xref>]; Nurfadhlina et al., 2006[<xref rid="R98" ref-type="bibr">98</xref>]). Canadian populations such as the natives (0.5 % (Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>])) and Caucasians (0.1 % (Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>])) showed the minimum frequency. However, this allele was not found in the African, Caucasian, Middle East and American mestizo populations (Aklillu et al., 2014[<xref rid="R1" ref-type="bibr">1</xref>]; Djordjevic et al., 2013[<xref rid="R31" ref-type="bibr">31</xref>], 2010[<xref rid="R30" ref-type="bibr">30</xref>]; Gyamfi et al., 2005[<xref rid="R45" ref-type="bibr">45</xref>]; Huang et al., 2005[<xref rid="R54" ref-type="bibr">54</xref>]; Malaiyandi et al., 2006[<xref rid="R80" ref-type="bibr">80</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Oscarson et al., 1999[<xref rid="R103" ref-type="bibr">103</xref>]; Rossini et al., 2006[<xref rid="R115" ref-type="bibr">115</xref>]).</p><p><italic>CYP2A6</italic>*6 has been found only in a Japanese population study at a low frequency (0.4 % (Kitagawa et al., 2001[<xref rid="R63" ref-type="bibr">63</xref>])). It not has been found in African (Gyamfi et al., 2005[<xref rid="R45" ref-type="bibr">45</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]), Caucasian (Malaiyandi et al., 2006[<xref rid="R80" ref-type="bibr">80</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]), Asian (Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Yoshida et al., 2002[<xref rid="R150" ref-type="bibr">150</xref>]) or Canadian native populations (Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]).</p><p><italic>CYP2A6</italic>*7 has a higher frequency in East and Southeast Asian populations such as Japanese (6.3-13 %) (Fujieda et al., 2004[<xref rid="R36" ref-type="bibr">36</xref>]; Fukami et al., 2005[<xref rid="R38" ref-type="bibr">38</xref>]; Minematsu et al., 2006[<xref rid="R84" ref-type="bibr">84</xref>]; Mwenifumbo et al., 2005[<xref rid="R88" ref-type="bibr">88</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]; Xu et al., 2002[<xref rid="R147" ref-type="bibr">147</xref>]; Yoshida et al., 2002[<xref rid="R150" ref-type="bibr">150</xref>]), Chinese (2.2-13.8 % (Liu et al., 2011[<xref rid="R74" ref-type="bibr">74</xref>]; Mwenifumbo et al., 2005[<xref rid="R88" ref-type="bibr">88</xref>]; Nurfadhlina et al., 2006[<xref rid="R98" ref-type="bibr">98</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]; Xu et al., 2002[<xref rid="R147" ref-type="bibr">147</xref>]; Yuan et al., 2016[<xref rid="R151" ref-type="bibr">151</xref>])), Korean (3.6-11.1 % (Djordjevic et al., 2013[<xref rid="R31" ref-type="bibr">31</xref>]; Fukami et al., 2005[<xref rid="R38" ref-type="bibr">38</xref>]; Mwenifumbo et al., 2005[<xref rid="R88" ref-type="bibr">88</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Yoshida et al., 2002[<xref rid="R150" ref-type="bibr">150</xref>])), Taiwanese (10 % (Mwenifumbo et al., 2005[<xref rid="R88" ref-type="bibr">88</xref>])), Thai (5-6.4 % (Mahavorasirikul et al., 2009[<xref rid="R79" ref-type="bibr">79</xref>]; Peamkrasatam et al., 2006[<xref rid="R107" ref-type="bibr">107</xref>])) and Malaysian (4.3 % (Nurfadhlina et al., 2006[<xref rid="R98" ref-type="bibr">98</xref>]; Yusof and Gan, 2009[<xref rid="R152" ref-type="bibr">152</xref>])) populations. It has also been reported in a lower frequency in Caucasian (&#x02264;0.3 % (Fukami, et al., 2005[<xref rid="R38" ref-type="bibr">38</xref>]; Malaiyandi et al., 2006[<xref rid="R80" ref-type="bibr">80</xref>]; Mwenifumbo et al., 2005[<xref rid="R88" ref-type="bibr">88</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]; Xu et al., 2002[<xref rid="R147" ref-type="bibr">147</xref>])) and M&#x00101;ori natives from New Zealand (1 % (Lea et al., 2008[<xref rid="R71" ref-type="bibr">71</xref>])). On the other hand, in Indian, African, Canadian native and Alaskan Yupik populations, this allele is not found (Binnington et al., 2012[<xref rid="R16" ref-type="bibr">16</xref>]; Fukami et al., 2005[<xref rid="R38" ref-type="bibr">38</xref>]; Gyamfi et al., 2005[<xref rid="R45" ref-type="bibr">45</xref>]; Mwenifumbo et al., 2005[<xref rid="R88" ref-type="bibr">88</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Nurfadhlina et al., 2006[<xref rid="R98" ref-type="bibr">98</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]).</p><p><italic>CYP2A6</italic>*8 has a specific frequency in Asian populations such as Malaysian (4.2-5 % (Nurfadhlina et al., 2006[<xref rid="R98" ref-type="bibr">98</xref>]; Yusof and Gan, 2009[<xref rid="R152" ref-type="bibr">152</xref>]), Chinese (&#x02264;3.6 % (Nurfadhlina et al., 2006[<xref rid="R98" ref-type="bibr">98</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]; Xu et al., 2002[<xref rid="R147" ref-type="bibr">147</xref>])), Japanese and Korean (&#x02264;2.2 % (Djordjevic et al., 2013[<xref rid="R31" ref-type="bibr">31</xref>]; Mwenifumbo et al., 2005[<xref rid="R88" ref-type="bibr">88</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]; Xu et al., 2002[<xref rid="R147" ref-type="bibr">147</xref>]; Yoshida et al., 2002[<xref rid="R150" ref-type="bibr">150</xref>])), Indian (0.9 % (Nurfadhlina et al., 2006[<xref rid="R98" ref-type="bibr">98</xref>])), Thai (&#x02264;0.5 % (Mahavorasirikul et al., 2009[<xref rid="R79" ref-type="bibr">79</xref>]; Peamkrasatam et al., 2006[<xref rid="R107" ref-type="bibr">107</xref>])) and is the lowest in Taiwanese (0.2 % (Mwenifumbo et al., 2005[<xref rid="R88" ref-type="bibr">88</xref>])). However, it has not been found in African, Caucasian, Canadian natives and Alaskan Yupik populations (Binnington et al., 2012[<xref rid="R16" ref-type="bibr">16</xref>]; Gyamfi et al., 2005[<xref rid="R45" ref-type="bibr">45</xref>]; Malaiyandi et al., 2006[<xref rid="R80" ref-type="bibr">80</xref>]; Mwenifumbo et al., 2005[<xref rid="R88" ref-type="bibr">88</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]; Xu et al., 2002[<xref rid="R147" ref-type="bibr">147</xref>]).</p><p><italic>CYP2A6</italic>*9 is the most widely studied decreased function allele. Asian populations show the highest frequency: East Asian populations (Chinese, Korean and Japanese) had a frequency between 15-20 % (Benowitz et al., 2006[<xref rid="R13" ref-type="bibr">13</xref>]; Djordjevic et al., 2013[<xref rid="R31" ref-type="bibr">31</xref>]; Fujieda et al., 2004[<xref rid="R36" ref-type="bibr">36</xref>]; Liu et al., 2011[<xref rid="R74" ref-type="bibr">74</xref>]; Minematsu et al., 2006[<xref rid="R84" ref-type="bibr">84</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Pitarque et al., 2001[<xref rid="R110" ref-type="bibr">110</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]; Yoshida et al., 2003[<xref rid="R149" ref-type="bibr">149</xref>]; Yuan et al., 2016[<xref rid="R151" ref-type="bibr">151</xref>]), followed by South Asian population as Thai (12.1-20.4 % (Mahavorasirikul et al., 2009[<xref rid="R79" ref-type="bibr">79</xref>]; Peamkrasatam et al., 2006[<xref rid="R107" ref-type="bibr">107</xref>])) and Malaysian (10.4 % (Yusof and Gan, 2009[<xref rid="R152" ref-type="bibr">152</xref>])); Middle East populations as Turkish (6.9-7.2 % (Pitarque et al., 2001[<xref rid="R110" ref-type="bibr">110</xref>]; von Richter et al., 2004[<xref rid="R142" ref-type="bibr">142</xref>])), Iranian (12.4 % (Emamghoreishi et al., 2008[<xref rid="R32" ref-type="bibr">32</xref>])) and some ethnic groups among them (Sepehr et al., 2004[<xref rid="R119" ref-type="bibr">119</xref>]) such as Turkomans (14 %), Turks (5 %) and Zoroastrian Persian (4 %) showed a high frequency. Mediterranean European (Spanish (Soriano et al., 2011[<xref rid="R124" ref-type="bibr">124</xref>]) and Serbian (Djordjevic et al., 2010[<xref rid="R30" ref-type="bibr">30</xref>])), North European (Swedish (Djordjevic et al., 2013[<xref rid="R31" ref-type="bibr">31</xref>]; Pitarque et al., 2001[<xref rid="R110" ref-type="bibr">110</xref>])) and Central European (Hungarian (Fiatal et al., 2016[<xref rid="R35" ref-type="bibr">35</xref>])) populations show a frequency range of 5-8 %, which is the same as Caucasian (Audrain-McGovern et al., 2007[<xref rid="R9" ref-type="bibr">9</xref>]; Benowitz et al., 2006[<xref rid="R13" ref-type="bibr">13</xref>]; Haberl et al., 2005[<xref rid="R46" ref-type="bibr">46</xref>]; Malaiyandi et al., 2006[<xref rid="R80" ref-type="bibr">80</xref>][<xref rid="R81" ref-type="bibr">81</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>], 2004[<xref rid="R95" ref-type="bibr">95</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]) and North American Caucasian populations (Bloom et al., 2011[<xref rid="R17" ref-type="bibr">17</xref>]; O'Loughlin et al., 2004[<xref rid="R99" ref-type="bibr">99</xref>]). A different pattern occurs in African populations; African and African American show a frequency of 7-10 % (Ho et al., 2009[<xref rid="R49" ref-type="bibr">49</xref>]; Mwenifumbo et al., 2008[<xref rid="R87" ref-type="bibr">87</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>], 2004[<xref rid="R95" ref-type="bibr">95</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]), but in populations with a more conserved African component as Ghanaian (5.7 % (Gyamfi et al., 2005[<xref rid="R45" ref-type="bibr">45</xref>])) and Ethiopian (2.8 % (Aklillu et al., 2014[<xref rid="R1" ref-type="bibr">1</xref>])) the frequency is lower. Amerindian populations such as Canadian natives (15.5 % (Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>])) and Alaskan Yupik (8.9 % (Binnington et al., 2012[<xref rid="R16" ref-type="bibr">16</xref>])) had a heterogeneous frequency, which was the same as American mestizo populations such as Brazilian (5.7 % (Vasconcelos et al., 2005[<xref rid="R139" ref-type="bibr">139</xref>])), Ecuadorian (10.3 % (Soriano et al., 2011[<xref rid="R124" ref-type="bibr">124</xref>])), Mexican (16.4 % (Svyryd et al., 2015[<xref rid="R126" ref-type="bibr">126</xref>])) and other Hispanics (7.1 % (Benowitz et al., 2006[<xref rid="R13" ref-type="bibr">13</xref>])). The only population in Oceania to report this allele is the native population M&#x00101;ori from New Zealand with 19 % (Lea et al., 2008[<xref rid="R71" ref-type="bibr">71</xref>]).</p><p><italic>CYP2A6</italic>*10 has been reported to be higher among Asian populations as Japanese (1-4.3 %) (Fujieda et al., 2004[<xref rid="R36" ref-type="bibr">36</xref>]; Mwenifumbo et al., 2005[<xref rid="R88" ref-type="bibr">88</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]; Xu et al., 2002[<xref rid="R147" ref-type="bibr">147</xref>]; Yoshida et al., 2002[<xref rid="R150" ref-type="bibr">150</xref>]), Chinese (0.4-4.3 % (Liu et al., 2011[<xref rid="R74" ref-type="bibr">74</xref>]; Mwenifumbo et al., 2005[<xref rid="R88" ref-type="bibr">88</xref>]; Nurfadhlina et al., 2006[<xref rid="R98" ref-type="bibr">98</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]; Xu et al., 2002[<xref rid="R147" ref-type="bibr">147</xref>])), Korean (0.5-4.2 %) (Djordjevic et al., 2013[<xref rid="R31" ref-type="bibr">31</xref>]; Mwenifumbo et al., 2005[<xref rid="R88" ref-type="bibr">88</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Yoshida et al., 2002[<xref rid="R150" ref-type="bibr">150</xref>]), Malaysian (4.3 %) (Nurfadhlina et al., 2006[<xref rid="R98" ref-type="bibr">98</xref>]), Taiwanese (4.1 %) (Mwenifumbo et al., 2005[<xref rid="R88" ref-type="bibr">88</xref>]) and Thai (1.6-2.4 %) (Mahavorasirikul et al., 2009[<xref rid="R79" ref-type="bibr">79</xref>]; Peamkrasatam et al., 2006[<xref rid="R107" ref-type="bibr">107</xref>]); and the Alaskan Yupik population with 1.9 % (Binnington et al., 2012[<xref rid="R16" ref-type="bibr">16</xref>]). However, Indian (Nurfadhlina et al., 2006[<xref rid="R98" ref-type="bibr">98</xref>]), Caucasian (Malaiyandi et al., 2006[<xref rid="R80" ref-type="bibr">80</xref>]; Mwenifumbo et al., 2005[<xref rid="R88" ref-type="bibr">88</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]; Xu et al., 2002[<xref rid="R147" ref-type="bibr">147</xref>]), African (Gyamfi et al., 2005[<xref rid="R45" ref-type="bibr">45</xref>]; Mwenifumbo et al., 2005[<xref rid="R88" ref-type="bibr">88</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]) and even Canadian native populations (Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]) do not show any frequency.</p><p><italic>CYP2A6</italic>*11 is not well-reported. However, it has been reported in a minimum frequency in Japanese and Korean populations at 0.5-0.7 % (Fujieda et al., 2004[<xref rid="R36" ref-type="bibr">36</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]). The few analyzed African and Caucasian populations did not report this allele.</p><p><italic>CYP2A6</italic>*12 has been reported at the highest frequency among the studied populations in Hispanics (3.5-4.7 % (Benowitz et al., 2006[<xref rid="R13" ref-type="bibr">13</xref>]; Koontz et al., 2009[<xref rid="R65" ref-type="bibr">65</xref>])) and Mexican (3.5 % (Borrego-Soto et al., 2015[<xref rid="R18" ref-type="bibr">18</xref>])) population. The frequency decreases in Caucasians (&#x02264;3 % (Audrain-McGovern et al., 2007[<xref rid="R9" ref-type="bibr">9</xref>]; Benowitz et al., 2006[<xref rid="R13" ref-type="bibr">13</xref>]; Haberl et al., 2005[<xref rid="R46" ref-type="bibr">46</xref>]; Koontz et al., 2009[<xref rid="R65" ref-type="bibr">65</xref>]; Malaiyandi et al., 2006[<xref rid="R80" ref-type="bibr">80</xref>][<xref rid="R81" ref-type="bibr">81</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>])), Spanish (2.2 % (Oscarson et al., 2002[<xref rid="R101" ref-type="bibr">101</xref>])) and Canadian populations (1.1 % (O'Loughlin et al., 2004[<xref rid="R99" ref-type="bibr">99</xref>])). Then, in Asians, similar to in Middle East populations such as Iranians, it is reported in 1.3 % (Emamghoreishi et al., 2008[<xref rid="R32" ref-type="bibr">32</xref>]), but in East Asia only Japanese had a minimum frequency (0.8 % (Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>])) while Chinese and Korean populations (Benowitz et al., 2006[<xref rid="R13" ref-type="bibr">13</xref>]; Koontz et al., 2009[<xref rid="R65" ref-type="bibr">65</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Oscarson et al., 2002[<xref rid="R101" ref-type="bibr">101</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]) did not report any frequency of the allele. Lastly, Amerindian populations such as Canadian natives and Alaskan Yupik reported a very low frequency (0.4-0.5 % (Binnington et al., 2012[<xref rid="R16" ref-type="bibr">16</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>])). In African populations, some studies show a low frequency (0.4 %) (Ho et al., 2009[<xref rid="R49" ref-type="bibr">49</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]) and others do not show any frequency (Benowitz et al., 2006[<xref rid="R13" ref-type="bibr">13</xref>]; Koontz et al., 2009[<xref rid="R65" ref-type="bibr">65</xref>]; Mwenifumbo et al., 2008[<xref rid="R87" ref-type="bibr">87</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]).</p><p><italic>CYP2A6</italic>*13 has been reported in Japanese (1.1-1.5 % (Kiyotani et al., 2002[<xref rid="R64" ref-type="bibr">64</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>])) and Koreans (0.2 % (Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>])). It was not found in Caucasians and Africans (Kiyotani et al., 2002[<xref rid="R64" ref-type="bibr">64</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]).</p><p><italic>CYP2A6</italic>*14 has a higher frequency in Caucasian (3.5-5.2 % (Haberl et al., 2005[<xref rid="R46" ref-type="bibr">46</xref>]; Kiyotani et al., 2002[<xref rid="R64" ref-type="bibr">64</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>])) than in African (0.9-1.4 % (Mwenifumbo et al., 2008[<xref rid="R87" ref-type="bibr">87</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>])), but was not reported in Asians (Japanese and Korean) (Kiyotani et al., 2002[<xref rid="R64" ref-type="bibr">64</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]).</p><p><italic>CYP2A6</italic>*15 has been reported at a minimum frequency in Japanese (1.5-2.2 % (Kiyotani et al., 2002[<xref rid="R64" ref-type="bibr">64</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>])) and Korean (1.2 % (Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>])), but not in Caucasian and African populations (Kiyotani et al., 2002[<xref rid="R64" ref-type="bibr">64</xref>]; Mwenifumbo et al., 2008[<xref rid="R87" ref-type="bibr">87</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]).</p><p><italic>CYP2A6</italic>*16 has been reported in Caucasian (0.3-3.6 %) and African (0-1.7 %) populations (Kiyotani et al., 2002[<xref rid="R64" ref-type="bibr">64</xref>]; Mwenifumbo et al., 2008[<xref rid="R87" ref-type="bibr">87</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]), but not in Japanese or Korean populations (Kiyotani et al., 2002[<xref rid="R64" ref-type="bibr">64</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]).</p><p><italic>CYP2A6</italic>*17 has a frequency of approximately 7.3-10.5 % in African populations (Fukami et al., 2004[<xref rid="R41" ref-type="bibr">41</xref>]; Ho et al., 2009[<xref rid="R49" ref-type="bibr">49</xref>]; Mwenifumbo et al., 2008[<xref rid="R87" ref-type="bibr">87</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]), but not in Caucasian, Korean, Japanese or Alaskan Yupik (Binnington et al., 2012[<xref rid="R16" ref-type="bibr">16</xref>]; Fukami et al., 2004[<xref rid="R41" ref-type="bibr">41</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]) populations.</p><p><italic>CYP2A6</italic>*18 has a higher frequency range in Caucasian (0.3-2.2 % (Fukami et al., 2005[<xref rid="R38" ref-type="bibr">38</xref>]; Haberl et al., 2005[<xref rid="R46" ref-type="bibr">46</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>])) than in Korean (0.3-0.5 % (Fukami et al., 2005[<xref rid="R38" ref-type="bibr">38</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>])), but has not been found in Japanese and African populations (Fukami et al., 2005[<xref rid="R38" ref-type="bibr">38</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]).</p><p><italic>CYP2A6</italic>*19 has been reported in a low frequency in Korean (1-1.4 % (Djordjevic et al., 2013[<xref rid="R31" ref-type="bibr">31</xref>]; Fukami et al., 2005[<xref rid="R38" ref-type="bibr">38</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>])) and Japanese (0.5 % ), but not in Caucasian nor African (Fukami et al., 2005[<xref rid="R38" ref-type="bibr">38</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]) populations.</p><p><italic>CYP2A6</italic>*20 is present in African population at a frequency range between 1-1.7 % (Fukami et al., 2005[<xref rid="R37" ref-type="bibr">37</xref>]; Ho et al., 2009[<xref rid="R49" ref-type="bibr">49</xref>]; Mwenifumbo et al., 2008[<xref rid="R87" ref-type="bibr">87</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]). This allele was not reported in Caucasian, Japanese and Korean populations (Fukami et al., 2005[<xref rid="R37" ref-type="bibr">37</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]).</p><p><italic>CYP2A6</italic>*21 has a higher frequency in Caucasian (0.5-2.3 %) (Al Koudsi et al., 2006[<xref rid="R3" ref-type="bibr">3</xref>]; Haberl et al., 2005[<xref rid="R46" ref-type="bibr">46</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]) than in African populations (0.6-0.7 % (Mwenifumbo et al., 2008[<xref rid="R87" ref-type="bibr">87</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>])). It has not been reported in Japanese or Korean (Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]) populations.</p><p><italic>CYP2A6</italic>*22 has been reported at frequency less than 0.3 % (Haberl et al., 2005[<xref rid="R2" ref-type="bibr">2</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]) in Caucasian populations, but not in Japanese or Korean (Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]) populations.</p><p><italic>CYP2A6</italic>*23 has a frequency range among 1-2 % (Ho et al., 2009[<xref rid="R49" ref-type="bibr">49</xref>], 2008[<xref rid="R50" ref-type="bibr">50</xref>]; Mwenifumbo et al., 2008[<xref rid="R87" ref-type="bibr">87</xref>]) in African populations, but was not reported in Caucasian, Japanese or Chinese populations (Ho et al., 2008[<xref rid="R50" ref-type="bibr">50</xref>]).</p><p><italic>CYP2A6</italic>*24 has a frequency range among 0.7-1.3 % in African populations (Al Koudsi et al., 2010[<xref rid="R2" ref-type="bibr">2</xref>]; Ho et al., 2009[<xref rid="R49" ref-type="bibr">49</xref>]; Mwenifumbo et al., 2008[<xref rid="R87" ref-type="bibr">87</xref>]), but it has not been found in Caucasian, Chinese, Japanese and Taiwanese (Al Koudsi et al., 2010[<xref rid="R2" ref-type="bibr">2</xref>]) populations.</p><p><italic>CYP2A6</italic>*25-*28 has only been reported in African populations, while <italic>CYP2A6</italic>*26-*27 has a frequency range of 0.7-0.9 % (Ho et al., 2009[<xref rid="R49" ref-type="bibr">49</xref>]; Mwenifumbo et al., 2008[<xref rid="R87" ref-type="bibr">87</xref>]) and <italic>CYP2A6</italic>*28 from 0.9-2.4 % (Ho et al., 2009[<xref rid="R49" ref-type="bibr">49</xref>]; Mwenifumbo et al., 2008[<xref rid="R87" ref-type="bibr">87</xref>]).</p><p><italic>CYP2A6</italic>*31, *34 and *38 have not been studied in any population.</p><p><italic>CYP2A6</italic>*35 has been reported at a frequency between 2.5-2.9 % (Al Koudsi et al., 2010[<xref rid="R2" ref-type="bibr">2</xref>]; Ho et al., 2009[<xref rid="R49" ref-type="bibr">49</xref>]) in African populations living in North American countries. In East Asian populations, such as Chinese, Japanese and Taiwanese, it has been found at a frequency of 0.5-0.8 % (Al Koudsi et al., 2010[<xref rid="R2" ref-type="bibr">2</xref>]), but it has not been found in Caucasian or Alaska Yupik (Al Koudsi et al., 2010[<xref rid="R2" ref-type="bibr">2</xref>]; Binnington et al., 2012[<xref rid="R16" ref-type="bibr">16</xref>]) populations.</p><p><italic>CYP2A6</italic>*36 and *37 has been reported in Taiwanese populations at a frequency of 0.3 %, but not in African, Caucasian, Chinese nor Japanese (Al Koudsi et al., 2010[<xref rid="R2" ref-type="bibr">2</xref>]) populations.</p><p><italic>CYP2A6</italic>*39 (0.6 %), *40 (0.2 %), *41 (1.2 %), *42 (0.2 %), *43 (0.2 %), *44 (0.2 %) and *45 (0.6 %) have only been reported in the African population (Piliguian et al., 2014[<xref rid="R109" ref-type="bibr">109</xref>]).</p><p>The gene duplication, <italic>CYP2A6</italic>*1X2, has been found at higher frequency in Asian populations as Asian (7.1 % (Benowitz et al., 2006[<xref rid="R13" ref-type="bibr">13</xref>])), Indian (3.5 % (Nurfadhlina et al., 2006[<xref rid="R98" ref-type="bibr">98</xref>])), Chinese (0.4-1.5 %) (Nurfadhlina et al., 2006[<xref rid="R98" ref-type="bibr">98</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]; Xu et al., 2002[<xref rid="R147" ref-type="bibr">147</xref>]), Korean (&#x02264;0.2 %) (Fukami et al., 2007[<xref rid="R40" ref-type="bibr">40</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]) and Malaysian (0.4 %) (Nurfadhlina et al., 2006[<xref rid="R98" ref-type="bibr">98</xref>]); the Hispanic population (3.5 %) (Benowitz et al., 2006[<xref rid="R13" ref-type="bibr">13</xref>]) has a higher frequency than the Ecuadorian population (0.5 %) (Soriano et al., 2011[<xref rid="R124" ref-type="bibr">124</xref>]); Caucasian populations have a frequency less than 2 % as in some Caucasian groups (&#x02264;1.7 %) (Benowitz et al., 2006[<xref rid="R13" ref-type="bibr">13</xref>]; Fukami et al., 2007[<xref rid="R40" ref-type="bibr">40</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Rao et al., 2000[<xref rid="R112" ref-type="bibr">112</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]; Xu et al., 2002[<xref rid="R147" ref-type="bibr">147</xref>]), Spanish (1.2 %) (Soriano et al., 2011[<xref rid="R124" ref-type="bibr">124</xref>]), Swedish (0.8 %) (Djordjevic et al., 2013[<xref rid="R31" ref-type="bibr">31</xref>]), Serbian (0.4 %) (Djordjevic et al., 2010[<xref rid="R30" ref-type="bibr">30</xref>]), North American (0.3 %) (Bloom et al., 2011[<xref rid="R17" ref-type="bibr">17</xref>]) and Canadian (0.2 %) (O'Loughlin et al., 2004[<xref rid="R99" ref-type="bibr">99</xref>]). In African populations, such African American (1.7 % (Fukami et al., 2007[<xref rid="R40" ref-type="bibr">40</xref>])) and Ethiopian (0.3 % (Aklillu et al., 2014[<xref rid="R1" ref-type="bibr">1</xref>])), this allele was present, but was not found in other African groups, Canadian natives or Alaskan Yupik (Binnington et al., 2012[<xref rid="R16" ref-type="bibr">16</xref>]; Nakajima et al., 2006[<xref rid="R91" ref-type="bibr">91</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]).</p><p>Most studies address the majority of a country's population as a general population. However, a few studies focus on more specific population classifications as ethnic and regional groups. In the Asian population, it was studied among Tottori, Shimane, Ehime and Fukuoka people of the respective districts of Yonago, Izumo, Matsuyama and Kurume located in Japan (Takeshita et al., 2006[<xref rid="R129" ref-type="bibr">129</xref>]). In China, it has been compared in the prevailing Han Chinese group and the Uighur, Bouyei and Tibetan ethnic groups (Pang et al., 2015[<xref rid="R105" ref-type="bibr">105</xref>]). In the South of India, the frequencies of the people from Andhra Pradesh, Karnataka, Kerala and Tamil Nadu regions (Krishnakumar et al., 2012[<xref rid="R67" ref-type="bibr">67</xref>]) were compared. In Iran, some ethnic groups such as Turkomans from the Golestan Province, Turks from the Ardabil Province and Zoroastrian Persians from Tehran (Sepehr et al., 2004[<xref rid="R119" ref-type="bibr">119</xref>]) were studied. In Russia, the Tatar ethnic group was reported (Korytina et al., 2014[<xref rid="R66" ref-type="bibr">66</xref>]). In African populations, the ethnic group Ovambo from Namibia was reported (Takeshita et al., 2006[<xref rid="R129" ref-type="bibr">129</xref>]); and some ethnic groups such as Akan, Guan, Ewe, Ga, Nzima and Dargarti, but there were a few participants that were added in a single Ghanaian population (Gyamfi et al., 2005[<xref rid="R45" ref-type="bibr">45</xref>]). In Oceania, the M&#x00101;ori ethnic group from New Zealand is the only population reported across the continent (Lea et al., 2008[<xref rid="R71" ref-type="bibr">71</xref>]). In the American continent, the ethnic groups such as Yupik from Alaska and Canadian natives have been reported (Binnington et al., 2012[<xref rid="R16" ref-type="bibr">16</xref>]; Nowak et al., 1998[<xref rid="R96" ref-type="bibr">96</xref>]; Schoedel et al., 2004[<xref rid="R117" ref-type="bibr">117</xref>]).</p></sec><sec><title>Conclusions and Perspectives</title><p>The enzyme responsible for metabolizing nicotine is mostly encoded by the <italic>CYP2A6</italic> gene, which is highly polymorphic. This variability is due to changes in DNA, which have generated different responses to nicotine and are reflected in the individual smoking behaviors along with other factors. It has been reported that this variability has been generated and distributed over a long time in different human populations, showing well defined ethnic patterns. Although association studies between carriers of certain variants and different smoking behaviors have been numerous with plausible results, population studies reporting frequencies of these variants are few. General population studies exhibit most reliable information than association studies with a variable frequency, because the population requirements are usually more specific, creating a population bias. However, it would be advisable to address this type of methodology in higher risk populations of smoking and those where policies to control smoking are less efficient, and where more smoking-related diseases are reported in the population. Additionally, the population must be characterized by more specific requirements, such as including the ancestry informative markers and avoiding "self-reporting" as the unique classification criteria. While there is a Human CYP-Allele Nomenclature Database in which the genetic findings of <italic>CYP2A6</italic> are unified, it is necessary to supplement it with updated data as per the population distribution. All of this could contribute to a personalized system that could detect, prevent and treat populations at risk of smoking, and in consequence, avoid tobacco consumption related diseases. </p></sec></body><back><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal">
<person-group><name><surname>Aklillu</surname><given-names>E</given-names></name><name><surname>Djordjevic</surname><given-names>N</given-names></name><name><surname>Carrillo</surname><given-names>JA</given-names></name><name><surname>Makonnen</surname><given-names>E</given-names></name><name><surname>Bertilsson</surname><given-names>L</given-names></name><name><surname>Ingelman-Sundberg</surname><given-names>M</given-names></name></person-group>
<article-title>High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population</article-title>
<source>OMICS</source>
<year>2014</year>
<volume>18</volume>
<fpage>446&#x02013;53</fpage>
<pub-id pub-id-type="pmid">24380444</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal">
<person-group><name><surname>Al Koudsi</surname><given-names>N</given-names></name><name><surname>Ahluwalia</surname><given-names>JS</given-names></name><name><surname>Lin</surname><given-names>S-K</given-names></name><name><surname>Sellers</surname><given-names>EM</given-names></name><name><surname>Tyndale</surname><given-names>RF</given-names></name></person-group>
<article-title>A novel CYP2A6 allele (CYP2A6*35) resulting in an amino acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo</article-title>
<source>Pharmacogenomics J</source>
<year>2010</year>
<volume>9</volume>
<fpage>274&#x02013;82</fpage>
</element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal">
<person-group><name><surname>Al Koudsi</surname><given-names>N</given-names></name><name><surname>Mwenifumbo</surname><given-names>JC</given-names></name><name><surname>Sellers</surname><given-names>EM</given-names></name><name><surname>Benowitz</surname><given-names>NL</given-names></name><name><surname>Swan</surname><given-names>GE</given-names></name><name><surname>Tyndale</surname><given-names>RF</given-names></name></person-group>
<article-title>Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics</article-title>
<source>Eur J Clin Pharmacol</source>
<year>2006</year>
<volume>62</volume>
<fpage>481&#x02013;4</fpage>
<pub-id pub-id-type="pmid">16758265</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal">
<person-group><name><surname>Al Koudsi</surname><given-names>N</given-names></name><name><surname>Tyndale</surname><given-names>RF</given-names></name></person-group>
<article-title>Genetic influences on smoking:a brief review</article-title>
<source>Ther Drug Monit</source>
<year>2005</year>
<volume>27</volume>
<fpage>704&#x02013;9</fpage>
<pub-id pub-id-type="pmid">16404798</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal">
<person-group><name><surname>Arinami</surname><given-names>T</given-names></name><name><surname>Ishiguro</surname><given-names>H</given-names></name><name><surname>Onaivi</surname><given-names>ES</given-names></name></person-group>
<article-title>Polymorphisms in genes involved in neurotransmission in relation to smoking</article-title>
<source>Eur J Pharmacol</source>
<year>2000</year>
<volume>410</volume>
<fpage>215</fpage>
<lpage>226</lpage>
<pub-id pub-id-type="pmid">11134671</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal">
<person-group><name><surname>Ariyoshi</surname><given-names>N</given-names></name><name><surname>Miyamoto</surname><given-names>M</given-names></name><name><surname>Umetsu</surname><given-names>Y</given-names></name><name><surname>Kunitoh</surname><given-names>H</given-names></name><name><surname>Dosaka-Akita</surname><given-names>H</given-names></name><name><surname>Sawamura</surname><given-names>Y-I</given-names></name><etal/></person-group>
<article-title>Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers</article-title>
<source>Cancer Epidemiol Biom Prev</source>
<year>2002</year>
<volume>11</volume>
<fpage>890&#x02013;4</fpage>
</element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal">
<person-group><name><surname>Ariyoshi</surname><given-names>N</given-names></name><name><surname>Sawamura</surname><given-names>Y</given-names></name><name><surname>Kamataki</surname><given-names>T</given-names></name></person-group>
<article-title>A novel single nucleotide polymorphism altering stability and activity of CYP2a6</article-title>
<source>Biochem Biophys Res Commun</source>
<year>2001</year>
<volume>281</volume>
<fpage>810&#x02013;4</fpage>
<pub-id pub-id-type="pmid">11237731</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal">
<person-group><name><surname>Ariyoshi</surname><given-names>N</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Miyamoto</surname><given-names>M</given-names></name><name><surname>Umetsu</surname><given-names>Y</given-names></name><name><surname>Daigo</surname><given-names>S</given-names></name><name><surname>Tateishi</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C</article-title>
<source>Pharmacogenetics</source>
<year>2000</year>
<volume>10</volume>
<fpage>687&#x02013;93</fpage>
<pub-id pub-id-type="pmid">11186131</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal">
<person-group><name><surname>Audrain-McGovern</surname><given-names>J</given-names></name><name><surname>Al Koudsi</surname><given-names>N</given-names></name><name><surname>Rodriguez</surname><given-names>D</given-names></name><name><surname>Wileyto</surname><given-names>EP</given-names></name><name><surname>Shields</surname><given-names>PG</given-names></name><name><surname>Tyndale</surname><given-names>RF</given-names></name></person-group>
<article-title>The role of CYP2A6 in the emergence of nicotine dependence in adolescents</article-title>
<source>Pediatrics</source>
<year>2007</year>
<volume>119</volume>
<fpage>e264</fpage>
<lpage>e274</lpage>
<pub-id pub-id-type="pmid">17130279</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal">
<person-group><name><surname>Benowitz</surname><given-names>NL</given-names></name></person-group>
<article-title>Cigarette smoking and nicotine addiction</article-title>
<source>Med Clin North Am</source>
<year>1992</year>
<volume>76</volume>
<fpage>415&#x02013;37</fpage>
<pub-id pub-id-type="pmid">1548969</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal">
<person-group><name><surname>Benowitz</surname><given-names>NL</given-names></name><name><surname>Jacob</surname><given-names>P</given-names><suffix>III</suffix></name></person-group>
<article-title>Metabolism of nicotine to cotinine studied by a dual stable isotope method</article-title>
<source>Clin Pharmacol Ther</source>
<year>1994</year>
<volume>56</volume>
<fpage>483&#x02013;93</fpage>
<pub-id pub-id-type="pmid">7955812</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal">
<person-group><name><surname>Benowitz</surname><given-names>NL</given-names></name><name><surname>Jacob</surname><given-names>P</given-names><suffix>III</suffix></name><name><surname>Sachs</surname><given-names>DP</given-names></name></person-group>
<article-title>Deficient C-oxidation of nicotine</article-title>
<source>Clin Pharmacol Ther</source>
<year>1995</year>
<volume>57</volume>
<fpage>590&#x02013;4</fpage>
<pub-id pub-id-type="pmid">7768082</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal">
<person-group><name><surname>Benowitz</surname><given-names>NL</given-names></name><name><surname>Swan</surname><given-names>GE</given-names></name><name><surname>Jacob</surname><given-names>P</given-names><suffix>III</suffix></name><name><surname>Lessov-Schlaggar</surname><given-names>CN</given-names></name><name><surname>Tyndale</surname><given-names>RF</given-names></name></person-group>
<article-title>CYP2A6 genotype and the metabolism and disposition kinetics of nicotine</article-title>
<source>Clin Pharmacol Ther</source>
<year>2006</year>
<volume>80</volume>
<fpage>457&#x02013;67</fpage>
<pub-id pub-id-type="pmid">17112802</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal">
<person-group><name><surname>Bhagwat</surname><given-names>SV</given-names></name><name><surname>Boyd</surname><given-names>MR</given-names></name><name><surname>Ravindranath</surname><given-names>V</given-names></name></person-group>
<article-title>Multiple forms of cytochrome P450 and associated monooxygenase activities in human brain mitochondria</article-title>
<source>Biochem Pharmacol</source>
<year>2000</year>
<volume>59</volume>
<fpage>573&#x02013;82</fpage>
<pub-id pub-id-type="pmid">10660123</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal">
<person-group><name><surname>Bierut</surname><given-names>LJ</given-names></name><name><surname>Johnson</surname><given-names>EO</given-names></name><name><surname>Saccone</surname><given-names>NL</given-names></name></person-group>
<article-title>A glimpse into the future - Personalized medicine for smoking cessation</article-title>
<source>Neuropharmacology</source>
<year>2014</year>
<volume>76B</volume>
<fpage>592&#x02013;9</fpage>
</element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal">
<person-group><name><surname>Binnington</surname><given-names>MJ</given-names></name><name><surname>Zhu</surname><given-names>AZX</given-names></name><name><surname>Renner</surname><given-names>CC</given-names></name><name><surname>Lanier</surname><given-names>AP</given-names></name><name><surname>Hatsukami</surname><given-names>DK</given-names></name><name><surname>Benowitz</surname><given-names>NL</given-names></name><etal/></person-group>
<article-title>CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people</article-title>
<source>Pharmacogenet Genom</source>
<year>2012</year>
<volume>22</volume>
<fpage>429&#x02013;40</fpage>
</element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal">
<person-group><name><surname>Bloom</surname><given-names>AJ</given-names></name><name><surname>Hinrichs</surname><given-names>AL</given-names></name><name><surname>Wang</surname><given-names>JC</given-names></name><name><surname>von Weymarn</surname><given-names>LB</given-names></name><name><surname>Kharasch</surname><given-names>ED</given-names></name><name><surname>Bierut</surname><given-names>LJ</given-names></name><etal/></person-group>
<article-title>The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European Americans</article-title>
<source>Pharmacogenet Genomics</source>
<year>2011</year>
<volume>21</volume>
<fpage>403&#x02013;16</fpage>
<pub-id pub-id-type="pmid">21597399</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal">
<person-group><name><surname>Borrego-Soto</surname><given-names>G</given-names></name><name><surname>Costilla-Esquivel</surname><given-names>A</given-names></name><name><surname>Padilla-Rivas</surname><given-names>GR</given-names></name><name><surname>C&#x000e1;zares-Samaniego</surname><given-names>PJ</given-names></name><name><surname>Posadas-Valay</surname><given-names>R</given-names></name><name><surname>Velasco-Casta&#x000f1;&#x000f3;n</surname><given-names>JG</given-names></name><etal/></person-group>
<article-title>An&#x000e1;lisis de frecuencias al&#x000e9;licas y genot&#x000ed;picas de las variantes CYP2A6*12 y rs16969968 de CHRNA5 y su asociaci&#x000f3;n con el h&#x000e1;bito de fumar y el IMC en sujetos j&#x000f3;venes del noreste de M&#x000e9;xico</article-title>
<source>Rev Med Chil</source>
<year>2015</year>
<volume>143</volume>
<fpage>1377&#x02013;85</fpage>
<pub-id pub-id-type="pmid">26757861</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal">
<person-group><name><surname>Bourian</surname><given-names>M</given-names></name><name><surname>Gullst&#x000e9;n</surname><given-names>H</given-names></name><name><surname>Legrum</surname><given-names>W</given-names></name></person-group>
<article-title>Genetic polymorphism of CYP2A6 in the German population</article-title>
<source>Toxicology</source>
<year>2000</year>
<volume>144</volume>
<fpage>129&#x02013;37</fpage>
<pub-id pub-id-type="pmid">10781880</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal">
<person-group><name><surname>C&#x000e1;ceres</surname><given-names>DD</given-names></name><name><surname>Alvarado</surname><given-names>SA</given-names></name><name><surname>Mart&#x000ed;nez</surname><given-names>P</given-names></name><name><surname>Qui&#x000f1;ones</surname><given-names>LA</given-names></name></person-group>
<article-title>Variantes gen&#x000e9;ticas de CYP2A6 y su relaci&#x000f3;n con la dependencia tab&#x000e1;quica y el h&#x000e1;bito de fumar en una muestra individuos chilenos. Un estudio piloto</article-title>
<source>Rev Med Chil</source>
<year>2012</year>
<volume>140</volume>
<fpage>436&#x02013;41</fpage>
<pub-id pub-id-type="pmid">22854688</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal">
<person-group><name><surname>Chenoweth</surname><given-names>MJ</given-names></name><name><surname>O&#x02019;Loughlin</surname><given-names>J</given-names></name><name><surname>Sylvestre</surname><given-names>M-P</given-names></name><name><surname>Tyndale</surname><given-names>RF</given-names></name></person-group>
<article-title>CYP2A6 slow nicotine metabolism is associated with increased quitting by adolescent smokers</article-title>
<source>Pharmacogenet Genom</source>
<year>2013</year>
<volume>23</volume>
<fpage>232&#x02013;5</fpage>
</element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal">
<person-group><name><surname>Chiang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>C-K</given-names></name><name><surname>Tsou</surname><given-names>T-C</given-names></name></person-group>
<article-title>Differential distribution of CYP2A6 and CYP2A13 in the human respiratory tract</article-title>
<source>Respiration</source>
<year>2012</year>
<volume>84</volume>
<fpage>319&#x02013;26</fpage>
<pub-id pub-id-type="pmid">22890016</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal">
<person-group><name><surname>Cok</surname><given-names>I</given-names></name><name><surname>Ayg&#x000fc;n Kocaba&#x0015f;</surname><given-names>N</given-names></name><name><surname>Cholerton</surname><given-names>S</given-names></name><name><surname>Karakaya</surname><given-names>AE</given-names></name><name><surname>Sarda&#x0015f;</surname><given-names>S</given-names></name></person-group>
<article-title>Determination of coumarin metabolism in Turkish population</article-title>
<source>Hum Exp Toxicol</source>
<year>2001</year>
<volume>20</volume>
<fpage>179&#x02013;84</fpage>
<pub-id pub-id-type="pmid">11393269</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal">
<person-group><name><surname>Crawford</surname><given-names>EL</given-names></name><name><surname>Weaver</surname><given-names>DA</given-names></name><name><surname>DeMuth</surname><given-names>JP</given-names></name><name><surname>Jackson</surname><given-names>CM</given-names></name><name><surname>Khuder</surname><given-names>SA</given-names></name><name><surname>Frampton</surname><given-names>MW</given-names></name><etal/></person-group>
<article-title>Measurement of cytochrome P450 2A6 and 2E1 gene expression in primary human bronchial epithelial cells</article-title>
<source>Carcinogenesis</source>
<year>1998</year>
<volume>19</volume>
<fpage>1867&#x02013;71</fpage>
<pub-id pub-id-type="pmid">9806171</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="webpage">
<source>CYP2A6 allele nomenclature</source>
<year>2014</year>
<comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.cypalleles.ki.se/cyp2a6.htm.">http://www.cypalleles.ki.se/cyp2a6.htm.</ext-link></comment>
</element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal">
<person-group><name><surname>Daigo</surname><given-names>S</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Fujieda</surname><given-names>M</given-names></name><name><surname>Ariyoshi</surname><given-names>N</given-names></name><name><surname>Yamazaki</surname><given-names>H</given-names></name><name><surname>Koizumi</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur</article-title>
<source>Pharmacogenetics</source>
<year>2002</year>
<volume>12</volume>
<fpage>299&#x02013;306</fpage>
<pub-id pub-id-type="pmid">12042667</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal">
<person-group><name><surname>Dempsey</surname><given-names>D</given-names></name><name><surname>Tutka</surname><given-names>P</given-names></name><name><surname>Jacob</surname><given-names>P</given-names></name><name><surname>Allen</surname><given-names>F</given-names></name><name><surname>Schoedel</surname><given-names>K</given-names></name><name><surname>Tyndale</surname><given-names>RF</given-names></name><etal/></person-group>
<article-title>Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity</article-title>
<source>Clin Pharmacol Ther</source>
<year>2004</year>
<volume>76</volume>
<fpage>64&#x02013;72</fpage>
<pub-id pub-id-type="pmid">15229465</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal">
<person-group><name><surname>di Iulio</surname><given-names>J</given-names></name><name><surname>Fayet</surname><given-names>A</given-names></name><name><surname>Arab-Alameddine</surname><given-names>M</given-names></name><name><surname>Rotger</surname><given-names>M</given-names></name><name><surname>Lubomirov</surname><given-names>R</given-names></name><name><surname>Cavassini</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function</article-title>
<source>Pharmacogenet Genom</source>
<year>2009</year>
<volume>19</volume>
<fpage>300&#x02013;9</fpage>
</element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal">
<person-group><name><surname>Ding</surname><given-names>X</given-names></name><name><surname>Kaminsky</surname><given-names>LS</given-names></name></person-group>
<article-title>Human extrahepatic cytochromes P450:function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts</article-title>
<source>Annu Rev Pharmacol Toxicol</source>
<year>2003</year>
<volume>43</volume>
<fpage>149&#x02013;73</fpage>
<pub-id pub-id-type="pmid">12171978</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal">
<person-group><name><surname>Djordjevic</surname><given-names>N</given-names></name><name><surname>Carrillo</surname><given-names>JA</given-names></name><name><surname>Gervasini</surname><given-names>G</given-names></name><name><surname>Jankovic</surname><given-names>S</given-names></name><name><surname>Aklillu</surname><given-names>E</given-names></name></person-group>
<article-title>In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population</article-title>
<source>Eur J Clin Pharmacol</source>
<year>2010</year>
<volume>66</volume>
<fpage>571&#x02013;8</fpage>
<pub-id pub-id-type="pmid">20155256</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal">
<person-group><name><surname>Djordjevic</surname><given-names>N</given-names></name><name><surname>Carrillo</surname><given-names>JA</given-names></name><name><surname>van den Broek</surname><given-names>MPJ</given-names></name><name><surname>Kishikawa</surname><given-names>J</given-names></name><name><surname>Roh</surname><given-names>H-K</given-names></name><name><surname>Bertilsson</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Comparisons of CYP2A6 genotype and enzyme activity between Swedes and Koreans</article-title>
<source>Drug Metab Pharmacokinet</source>
<year>2013</year>
<volume>28</volume>
<fpage>93&#x02013;7</fpage>
<pub-id pub-id-type="pmid">22850738</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal">
<person-group><name><surname>Emamghoreishi</surname><given-names>M</given-names></name><name><surname>Bokaee</surname><given-names>H-R</given-names></name><name><surname>Keshavarz</surname><given-names>M</given-names></name><name><surname>Ghaderi</surname><given-names>A</given-names></name><name><surname>Tyndale</surname><given-names>RF</given-names></name></person-group>
<article-title>CYP2A6 allele frequencies in an Iranian population</article-title>
<source>Arch Iran Med</source>
<year>2008</year>
<volume>11</volume>
<fpage>613&#x02013;7</fpage>
<pub-id pub-id-type="pmid">18976031</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal">
<person-group><name><surname>Evans</surname><given-names>WE</given-names></name><name><surname>Relling</surname><given-names>MV</given-names></name></person-group>
<article-title>Moving towards individualized medicine with pharmacogenomics</article-title>
<source>Nature</source>
<year>2004</year>
<volume>429</volume>
<fpage>464&#x02013;8</fpage>
<pub-id pub-id-type="pmid">15164072</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal">
<person-group><name><surname>Fernandez-Salguero</surname><given-names>P</given-names></name><name><surname>Hoffman</surname><given-names>SM</given-names></name><name><surname>Cholerton</surname><given-names>S</given-names></name><name><surname>Mohrenweiser</surname><given-names>H</given-names></name><name><surname>Raunio</surname><given-names>H</given-names></name><name><surname>Rautio</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>A genetic polymorphism in coumarin 7-hydroxylation:sequence of the human CYP2A genes and identification of variant CYP2A6 alleles</article-title>
<source>Am J Hum Genet</source>
<year>1995</year>
<volume>57</volume>
<fpage>651&#x02013;60</fpage>
<pub-id pub-id-type="pmid">7668294</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal">
<person-group><name><surname>Fiatal</surname><given-names>S</given-names></name><name><surname>T&#x000f3;th</surname><given-names>R</given-names></name><name><surname>Moravcsik-Kornyicki</surname><given-names>&#x000c1;</given-names></name><name><surname>K&#x000f3;sa</surname><given-names>Z</given-names></name><name><surname>S&#x000e1;ndor</surname><given-names>J</given-names></name><name><surname>McKee</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>High prevalence of smoking in the Roma population seems to have no genetic background</article-title>
<source>Nicotine Tob Res</source>
<year>2016</year>
<volume>18</volume>
<fpage>2260</fpage>
<lpage>2267</lpage>
<pub-id pub-id-type="pmid">27613936</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal">
<person-group><name><surname>Fujieda</surname><given-names>M</given-names></name><name><surname>Yamazaki</surname><given-names>H</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Kiyotani</surname><given-names>K</given-names></name><name><surname>Gyamfi</surname><given-names>MA</given-names></name><name><surname>Sakurai</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers</article-title>
<source>Carcinogenesis</source>
<year>2004</year>
<volume>25</volume>
<fpage>2451&#x02013;8</fpage>
<pub-id pub-id-type="pmid">15308589</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal">
<person-group><name><surname>Fukami</surname><given-names>T</given-names></name><name><surname>Nakajima</surname><given-names>M</given-names></name><name><surname>Higashi</surname><given-names>E</given-names></name><name><surname>Yamanaka</surname><given-names>H</given-names></name><name><surname>McLeod</surname><given-names>HL</given-names></name><name><surname>Yokoi</surname><given-names>T</given-names></name></person-group>
<article-title>A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity</article-title>
<source>Biochem Pharmacol</source>
<year>2005</year>
<volume>70</volume>
<fpage>801&#x02013;8</fpage>
<pub-id pub-id-type="pmid">15993850</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal">
<person-group><name><surname>Fukami</surname><given-names>T</given-names></name><name><surname>Nakajima</surname><given-names>M</given-names></name><name><surname>Higashi</surname><given-names>E</given-names></name><name><surname>Yamanaka</surname><given-names>H</given-names></name><name><surname>Sakai</surname><given-names>H</given-names></name><name><surname>Mcleod</surname><given-names>HL</given-names></name><etal/></person-group>
<article-title>Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity</article-title>
<source>Drug Metab Dispos</source>
<year>2005</year>
<volume>33</volume>
<fpage>1202&#x02013;10</fpage>
<pub-id pub-id-type="pmid">15900015</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal">
<person-group><name><surname>Fukami</surname><given-names>T</given-names></name><name><surname>Nakajima</surname><given-names>M</given-names></name><name><surname>Sakai</surname><given-names>H</given-names></name><name><surname>McLeod</surname><given-names>HL</given-names></name><name><surname>Yokoi</surname><given-names>T</given-names></name></person-group>
<article-title>CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele</article-title>
<source>Pharmacogenom J</source>
<year>2006</year>
<volume>6</volume>
<fpage>401&#x02013;12</fpage>
</element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal">
<person-group><name><surname>Fukami</surname><given-names>T</given-names></name><name><surname>Nakajima</surname><given-names>M</given-names></name><name><surname>Yamanaka</surname><given-names>H</given-names></name><name><surname>Fukushima</surname><given-names>Y</given-names></name><name><surname>McLeod</surname><given-names>HL</given-names></name><name><surname>Yokoi</surname><given-names>T</given-names></name></person-group>
<article-title>A novel duplication type of CYP2A6 gene in African-American population</article-title>
<source>Drug Metab Dispos</source>
<year>2007</year>
<volume>35</volume>
<fpage>515&#x02013;20</fpage>
<pub-id pub-id-type="pmid">17267622</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal">
<person-group><name><surname>Fukami</surname><given-names>T</given-names></name><name><surname>Nakajima</surname><given-names>M</given-names></name><name><surname>Yoshida</surname><given-names>R</given-names></name><name><surname>Tsuchiya</surname><given-names>Y</given-names></name><name><surname>Fujiki</surname><given-names>Y</given-names></name><name><surname>Katoh</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo</article-title>
<source>Clin Pharmacol Ther</source>
<year>2004</year>
<volume>76</volume>
<fpage>519&#x02013;27</fpage>
<pub-id pub-id-type="pmid">15592323</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal">
<person-group><name><surname>Gambier</surname><given-names>N</given-names></name><name><surname>Batt</surname><given-names>A-M</given-names></name><name><surname>Marie</surname><given-names>B</given-names></name><name><surname>Pfister</surname><given-names>M</given-names></name><name><surname>Siest</surname><given-names>G</given-names></name><name><surname>Visvikis-Siest</surname><given-names>S</given-names></name></person-group>
<article-title>Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort</article-title>
<source>Pharmacogenom J</source>
<year>2005</year>
<volume>5</volume>
<fpage>271&#x02013;5</fpage>
</element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal">
<person-group><name><surname>Gu</surname><given-names>DF</given-names></name><name><surname>Hinks</surname><given-names>LJ</given-names></name><name><surname>Morton</surname><given-names>NE</given-names></name><name><surname>Day</surname><given-names>INM</given-names></name></person-group>
<article-title>The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit</article-title>
<source>Ann Hum Genet</source>
<year>2000</year>
<volume>64</volume>
<fpage>383&#x02013;90</fpage>
<pub-id pub-id-type="pmid">11281276</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal">
<person-group><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Lai</surname><given-names>B</given-names></name><name><surname>Zhan</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group>
<article-title xml:lang="de"/>
<trans-title>Frequency of CYP2A6 gene deletion and its relation to risk of lung cancer</trans-title>
<source>Zhongguo Fei Ai Za Zhi</source>
<year>2005</year>
<volume>8</volume>
<fpage>297&#x02013;9</fpage>
<pub-id pub-id-type="pmid">21108885</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal">
<person-group><name><surname>Gyamfi</surname><given-names>MA</given-names></name><name><surname>Fujieda</surname><given-names>M</given-names></name><name><surname>Kiyotani</surname><given-names>K</given-names></name><name><surname>Yamazaki</surname><given-names>H</given-names></name><name><surname>Kamataki</surname><given-names>T</given-names></name></person-group>
<article-title>High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana</article-title>
<source>Eur J of Clin Pharmacol</source>
<year>2005</year>
<volume>60</volume>
<fpage>855&#x02013;7</fpage>
<pub-id pub-id-type="pmid">15660270</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal">
<person-group><name><surname>Haberl</surname><given-names>M</given-names></name><name><surname>Anwald</surname><given-names>B</given-names></name><name><surname>Klein</surname><given-names>K</given-names></name><name><surname>Weil</surname><given-names>R</given-names></name><name><surname>Fuss</surname><given-names>C</given-names></name><name><surname>Gepdiremen</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Three haplotypes associated with CYP2A6 phenotypes in Caucasians</article-title>
<source>Pharmacogenet Genom</source>
<year>2005</year>
<volume>15</volume>
<fpage>609&#x02013;24</fpage>
</element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal">
<person-group><name><surname>Hadidi</surname><given-names>H</given-names></name><name><surname>Zahlsen</surname><given-names>K</given-names></name><name><surname>Idle</surname><given-names>JR</given-names></name><name><surname>Cholerton</surname><given-names>S</given-names></name></person-group>
<article-title>A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin</article-title>
<source>Food Chem Toxicol</source>
<year>1997</year>
<volume>35</volume>
<fpage>903&#x02013;7</fpage>
<pub-id pub-id-type="pmid">9409631</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal">
<person-group><name><surname>Heravi</surname><given-names>RE</given-names></name><name><surname>Ramezani</surname><given-names>M</given-names></name><name><surname>Behravan</surname><given-names>J</given-names></name></person-group>
<article-title>Association between nicotine metabolism and CYP2A6*1 and CYP2A6*4 genotypes in an Iranian population</article-title>
<source>DNA Cell Biol</source>
<year>2010</year>
<volume>29</volume>
<fpage>369&#x02013;73</fpage>
<pub-id pub-id-type="pmid">20438369</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal">
<person-group><name><surname>Ho</surname><given-names>MK</given-names></name><name><surname>Mwenifumbo</surname><given-names>JC</given-names></name><name><surname>Al Koudsi</surname><given-names>N</given-names></name><name><surname>Okuyemi</surname><given-names>KS</given-names></name><name><surname>Ahluwalia</surname><given-names>JS</given-names></name><name><surname>Benowitz</surname><given-names>NL</given-names></name><etal/></person-group>
<article-title>Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers</article-title>
<source>Clin Pharmacol Ther</source>
<year>2009</year>
<volume>85</volume>
<fpage>635&#x02013;43</fpage>
<pub-id pub-id-type="pmid">19279561</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal">
<person-group><name><surname>Ho</surname><given-names>MK</given-names></name><name><surname>Mwenifumbo</surname><given-names>JC</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Gillam</surname><given-names>EMJ</given-names></name><name><surname>Tyndale</surname><given-names>RF</given-names></name></person-group>
<article-title>A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent</article-title>
<source>Pharmacogenet Genom</source>
<year>2008</year>
<volume>18</volume>
<fpage>67&#x02013;75</fpage>
</element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal">
<person-group><name><surname>Hoffman</surname><given-names>SM</given-names></name><name><surname>Fernandez-Salguero</surname><given-names>P</given-names></name><name><surname>Gonzalez</surname><given-names>FJ</given-names></name><name><surname>Mohrenweiser</surname><given-names>HW</given-names></name></person-group>
<article-title>Organization and evolution of the cytochrome P450 CYP2A-2B-2F subfamily gene cluster on human chromosome 19</article-title>
<source>J Mol Evol</source>
<year>1995</year>
<volume>41</volume>
<fpage>894&#x02013;900</fpage>
<pub-id pub-id-type="pmid">8587134</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal">
<person-group><name><surname>Hoffman</surname><given-names>SM</given-names></name><name><surname>Nelson</surname><given-names>DR</given-names></name><name><surname>Keeney</surname><given-names>DS</given-names></name></person-group>
<article-title>Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19</article-title>
<source>Pharmacogenetics</source>
<year>2001</year>
<volume>11</volume>
<fpage>687&#x02013;98</fpage>
<pub-id pub-id-type="pmid">11692077</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal">
<person-group><name><surname>Hosono</surname><given-names>H</given-names></name><name><surname>Kumondai</surname><given-names>M</given-names></name><name><surname>Arai</surname><given-names>T</given-names></name><name><surname>Sugimura</surname><given-names>H</given-names></name><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Hirasawa</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>CYP2A6 genetic polymorphism is associated with decreased susceptibility to squamous cell lung cancer in Japanese smokers</article-title>
<source>Drug Metab Pharmacokinet</source>
<year>2015</year>
<volume>30</volume>
<fpage>263&#x02013;8</fpage>
<pub-id pub-id-type="pmid">26091970</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal">
<person-group><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Cook</surname><given-names>DG</given-names></name><name><surname>Hinks</surname><given-names>LJ</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Ye</surname><given-names>S</given-names></name><name><surname>Gilg</surname><given-names>JA</given-names></name><etal/></person-group>
<article-title>CYP2A6, MAOA, DBH, DRD4, and 5HT2A genotypes, smoking behaviour and cotinine levels in 1518 UK adolescents</article-title>
<source>Pharmacogenet Genom</source>
<year>2005</year>
<volume>15</volume>
<fpage>839&#x02013;50</fpage>
</element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal">
<person-group><name><surname>Hukkanen</surname><given-names>J</given-names></name><name><surname>Jacob</surname><given-names>P</given-names><suffix>III</suffix></name><name><surname>Benowitz</surname><given-names>NL</given-names></name></person-group>
<article-title>Metabolism and disposition kinetics of nicotine</article-title>
<source>Pharmacol Rev</source>
<year>2005</year>
<volume>57</volume>
<fpage>79&#x02013;115</fpage>
<pub-id pub-id-type="pmid">15734728</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal">
<person-group><name><surname>Ingelman-Sundberg</surname><given-names>M</given-names></name></person-group>
<article-title>Pharmacogenetics of cytochrome P450 and its applications in drug therapy:the past, present and future</article-title>
<source>Trends Pharmacol Sci</source>
<year>2004</year>
<volume>25</volume>
<fpage>193&#x02013;200</fpage>
<pub-id pub-id-type="pmid">15063083</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal">
<person-group><name><surname>Ingelman-Sundberg</surname><given-names>M</given-names></name></person-group>
<article-title>Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy</article-title>
<source>J Intern Med</source>
<year>2001</year>
<volume>250</volume>
<fpage>186&#x02013;200</fpage>
<pub-id pub-id-type="pmid">11555122</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal">
<person-group><name><surname>Ingelman-Sundberg</surname><given-names>M</given-names></name></person-group>
<article-title>The human genome project and novel aspects of cytochrome P450 research</article-title>
<source>Toxicol Appl Pharmacol</source>
<year>2005</year>
<volume>207</volume>
<issue>2 Suppl</issue>
<fpage>52&#x02013;6</fpage>
<pub-id pub-id-type="pmid">15993453</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal">
<person-group><name><surname>Islam</surname><given-names>MS</given-names></name><name><surname>Ahmed</surname><given-names>MU</given-names></name><name><surname>Sayeed</surname><given-names>MS</given-names></name><name><surname>Maruf</surname><given-names>AA</given-names></name><name><surname>Mostofa</surname><given-names>AG</given-names></name><name><surname>Hussain</surname><given-names>SM</given-names></name><etal/></person-group>
<article-title>Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population</article-title>
<source>Clin Chim Acta</source>
<year>2013</year>
<volume>416</volume>
<fpage>11&#x02013;9</fpage>
<pub-id pub-id-type="pmid">23178447</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal">
<person-group><name><surname>Ito</surname><given-names>T</given-names></name><name><surname>Tsuji</surname><given-names>M</given-names></name><name><surname>Mori</surname><given-names>Y</given-names></name><name><surname>Kanda</surname><given-names>H</given-names></name><name><surname>Hidaka</surname><given-names>T</given-names></name><name><surname>Kakamu</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Effect of CYP2A6*4 genetic polymorphisms on smoking behaviors and nicotine dependence in a general population of japanese men</article-title>
<source>Fukushima J Med Sci</source>
<year>2015</year>
<volume>61</volume>
<fpage>125&#x02013;30</fpage>
<pub-id pub-id-type="pmid">26370685</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal">
<person-group><name><surname>Iwahashi</surname><given-names>K</given-names></name><name><surname>Waga</surname><given-names>C</given-names></name><name><surname>Takimoto</surname><given-names>T</given-names></name></person-group>
<article-title>Whole deletion of CYP2A6 gene (CYP2A6*4C) and smoking behavior</article-title>
<source>Neuropsychobiology</source>
<year>2004</year>
<volume>49</volume>
<fpage>101&#x02013;4</fpage>
<pub-id pub-id-type="pmid">14981342</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal">
<person-group><name><surname>Kitagawa</surname><given-names>K</given-names></name><name><surname>Kunugita</surname><given-names>N</given-names></name><name><surname>Katoh</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Kawamoto</surname><given-names>T</given-names></name></person-group>
<article-title>The significance of the homozygous CYP2A6 deletion on nicotine metabolism:a new genotyping method of CYP2A6 using a single PCR-RFLP</article-title>
<source>Biochem Biophys Res Commun</source>
<year>1999</year>
<volume>262</volume>
<fpage>146&#x02013;51</fpage>
<pub-id pub-id-type="pmid">10448083</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal">
<person-group><name><surname>Kitagawa</surname><given-names>K</given-names></name><name><surname>Kunugita</surname><given-names>N</given-names></name><name><surname>Kitagawa</surname><given-names>M</given-names></name><name><surname>Kawamoto</surname><given-names>T</given-names></name></person-group>
<article-title>CYP2A6*6, a novel polymorphism in cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity</article-title>
<source>J Biol Chem</source>
<year>2001</year>
<volume>276</volume>
<fpage>17830&#x02013;5</fpage>
<pub-id pub-id-type="pmid">11278503</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal">
<person-group><name><surname>Kiyotani</surname><given-names>K</given-names></name><name><surname>Fujieda</surname><given-names>M</given-names></name><name><surname>Yamazaki</surname><given-names>H</given-names></name><name><surname>Shimada</surname><given-names>T</given-names></name><name><surname>Guengerich</surname><given-names>FP</given-names></name><name><surname>Parkinson</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Twenty one novel single nucleotide polymorphisms (SNPs) of the CYP2A6 gene in Japanese and Caucasians</article-title>
<source>Drug Metab Pharmacokinet</source>
<year>2002</year>
<volume>17</volume>
<fpage>482&#x02013;7</fpage>
<pub-id pub-id-type="pmid">15618701</pub-id></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal">
<person-group><name><surname>Koontz</surname><given-names>DA</given-names></name><name><surname>Huckins</surname><given-names>JJ</given-names></name><name><surname>Spencer</surname><given-names>A</given-names></name><name><surname>Gallagher</surname><given-names>ML</given-names></name></person-group>
<article-title>Rapid detection of the CYP2A6*12 hybrid allele by Pyrosequencing technology</article-title>
<source>BMC Med Genet</source>
<year>2009</year>
<volume>10</volume>
<fpage>80</fpage>
<pub-id pub-id-type="pmid">19703308</pub-id></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal">
<person-group><name><surname>Korytina</surname><given-names>GF</given-names></name><name><surname>Akhmadishina</surname><given-names>LZ</given-names></name><name><surname>Kochetova</surname><given-names>OV</given-names></name><name><surname>Burduk</surname><given-names>YV</given-names></name><name><surname>Aznabaeva</surname><given-names>YG</given-names></name><name><surname>Zagidullin</surname><given-names>SZ</given-names></name><etal/></person-group>
<article-title>Association of genes involved in nicotine and tobacco smoke toxicant metabolism (CHRNA3/5, CYP2A6, and NQO1) and DNA repair (XRCC1, XRCC3, XPC, and XPA) with chronic obstructive pulmonary disease</article-title>
<source>Mol Biol</source>
<year>2014</year>
<volume>48</volume>
<fpage>823&#x02013;34</fpage>
</element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="journal">
<person-group><name><surname>Krishnakumar</surname><given-names>D</given-names></name><name><surname>Gurusamy</surname><given-names>U</given-names></name><name><surname>Dhandapani</surname><given-names>K</given-names></name><name><surname>Surendiran</surname><given-names>A</given-names></name><name><surname>Baghel</surname><given-names>R</given-names></name><name><surname>Kukreti</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Genetic polymorphisms of drug-metabolizing phase I enzymes CYP2E1, CYP2A6 and CYP3A5 in South Indian population</article-title>
<source>Fund Clin Pharmacol</source>
<year>2012</year>
<volume>26</volume>
<fpage>295&#x02013;306</fpage>
</element-citation></ref><ref id="R68"><label>68</label><element-citation publication-type="journal">
<person-group><name><surname>Kubota</surname><given-names>T</given-names></name><name><surname>Nakajima-Taniguchi</surname><given-names>C</given-names></name><name><surname>Fukuda</surname><given-names>T</given-names></name><name><surname>Funamoto</surname><given-names>M</given-names></name><name><surname>Maeda</surname><given-names>M</given-names></name><name><surname>Tange</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation</article-title>
<source>Pharmacogenom J</source>
<year>2006</year>
<volume>6</volume>
<fpage>115&#x02013;9</fpage>
</element-citation></ref><ref id="R69"><label>69</label><element-citation publication-type="journal">
<person-group><name><surname>Kumondai</surname><given-names>M</given-names></name><name><surname>Hosono</surname><given-names>H</given-names></name><name><surname>Orikasa</surname><given-names>K</given-names></name><name><surname>Arai</surname><given-names>Y</given-names></name><name><surname>Arai</surname><given-names>T</given-names></name><name><surname>Sugimura</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Genetic polymorphisms of CYP2A6 in a case-control study on bladder cancer in Japanese smokers</article-title>
<source>Biol Pharm Bull</source>
<year>2016</year>
<volume>39</volume>
<fpage>84&#x02013;9</fpage>
<pub-id pub-id-type="pmid">26725431</pub-id></element-citation></ref><ref id="R70"><label>70</label><element-citation publication-type="journal">
<person-group><name><surname>Kwon</surname><given-names>J-T</given-names></name><name><surname>Nakajima</surname><given-names>M</given-names></name><name><surname>Chai</surname><given-names>S</given-names></name><name><surname>Yom</surname><given-names>Y-K</given-names></name><name><surname>Kim</surname><given-names>H-K</given-names></name><name><surname>Yamazaki</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Nicotine metabolism and CYP2A6 allele frequencies in Koreans</article-title>
<source>Pharmacogenetics</source>
<year>2001</year>
<volume>11</volume>
<fpage>317&#x02013;23</fpage>
<pub-id pub-id-type="pmid">11434509</pub-id></element-citation></ref><ref id="R71"><label>71</label><element-citation publication-type="journal">
<person-group><name><surname>Lea</surname><given-names>RA</given-names></name><name><surname>Roberts</surname><given-names>RL</given-names></name><name><surname>Green</surname><given-names>MR</given-names></name><name><surname>Kennedy</surname><given-names>MA</given-names></name><name><surname>Chambers</surname><given-names>GK</given-names></name></person-group>
<article-title>Allele frequency differences of cytochrome P450 polymorphisms in a sample of New Zealand M&#x00101;ori</article-title>
<source>N Z Med J</source>
<year>2008</year>
<volume>121</volume>
<fpage>33&#x02013;7</fpage>
</element-citation></ref><ref id="R72"><label>72</label><element-citation publication-type="journal">
<person-group><name><surname>Lerman</surname><given-names>C</given-names></name><name><surname>Jepson</surname><given-names>C</given-names></name><name><surname>Wileyto</surname><given-names>EP</given-names></name><name><surname>Patterson</surname><given-names>F</given-names></name><name><surname>Schnoll</surname><given-names>R</given-names></name><name><surname>Mroziewicz</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy</article-title>
<source>Clin Pharmacol Ther</source>
<year>2010</year>
<volume>87</volume>
<fpage>553&#x02013;7</fpage>
<pub-id pub-id-type="pmid">20336063</pub-id></element-citation></ref><ref id="R73"><label>73</label><element-citation publication-type="journal">
<person-group><name><surname>Lerman</surname><given-names>C</given-names></name><name><surname>Niaura</surname><given-names>R</given-names></name></person-group>
<article-title>Applying genetic approaches to the treatment of nicotine dependence</article-title>
<source>Oncogene</source>
<year>2002</year>
<volume>21</volume>
<fpage>7412&#x02013;20</fpage>
<pub-id pub-id-type="pmid">12379882</pub-id></element-citation></ref><ref id="R74"><label>74</label><element-citation publication-type="journal">
<person-group><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>David</surname><given-names>SP</given-names></name><name><surname>Tyndale</surname><given-names>RF</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Ding</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Associations of CYP2A6 genotype with smoking behaviors in southern China</article-title>
<source>Addiction</source>
<year>2011</year>
<volume>106</volume>
<fpage>985&#x02013;94</fpage>
<pub-id pub-id-type="pmid">21205058</pub-id></element-citation></ref><ref id="R75"><label>75</label><element-citation publication-type="journal">
<person-group><name><surname>London</surname><given-names>SJ</given-names></name><name><surname>Idle</surname><given-names>JR</given-names></name><name><surname>Daly</surname><given-names>AK</given-names></name><name><surname>Coetzee</surname><given-names>GA</given-names></name></person-group>
<article-title>Genetic variation of CYP2A6, smoking, and risk of cancer</article-title>
<source>The Lancet</source>
<year>1999</year>
<volume>353</volume>
<fpage>898&#x02013;9</fpage>
</element-citation></ref><ref id="R76"><label>76</label><element-citation publication-type="journal">
<person-group><name><surname>Loriot</surname><given-names>MA</given-names></name><name><surname>Rebuissou</surname><given-names>S</given-names></name><name><surname>Oscarson</surname><given-names>M</given-names></name><name><surname>Cen&#x000e9;e</surname><given-names>S</given-names></name><name><surname>Miyamoto</surname><given-names>M</given-names></name><name><surname>Ariyoshi</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population</article-title>
<source>Pharmacogenetics</source>
<year>2001</year>
<volume>11</volume>
<fpage>39&#x02013;44</fpage>
<pub-id pub-id-type="pmid">11207029</pub-id></element-citation></ref><ref id="R77"><label>77</label><element-citation publication-type="journal">
<person-group><name><surname>Lourembam</surname><given-names>DS</given-names></name><name><surname>Singh</surname><given-names>AR</given-names></name><name><surname>Sharma</surname><given-names>TD</given-names></name><name><surname>Singh</surname><given-names>TS</given-names></name><name><surname>Singh</surname><given-names>TR</given-names></name><name><surname>Singh</surname><given-names>LS</given-names></name></person-group>
<article-title>Evaluation of risk factors for nasopharyngeal carcinoma in a high-risk area of India, the northeastern region</article-title>
<source>Asian Pacif J Cancer Prev: APJCP</source>
<year>2015</year>
<volume>16</volume>
<fpage>4927&#x02013;35</fpage>
</element-citation></ref><ref id="R78"><label>78</label><element-citation publication-type="journal">
<person-group><name><surname>Mac&#x000e9;</surname><given-names>K</given-names></name><name><surname>Bowman</surname><given-names>ED</given-names></name><name><surname>Vautravers</surname><given-names>P</given-names></name><name><surname>Shields</surname><given-names>PG</given-names></name><name><surname>Harris</surname><given-names>CC</given-names></name><name><surname>Pfeifer</surname><given-names>AMA</given-names></name></person-group>
<article-title>Characterisation of xenobiotic-metabolising enzyme expression in human bronchial mucosa and peripheral lung tissues</article-title>
<source>Eur J Cancer</source>
<year>1998</year>
<volume>34</volume>
<fpage>914&#x02013;20</fpage>
<pub-id pub-id-type="pmid">9797707</pub-id></element-citation></ref><ref id="R79"><label>79</label><element-citation publication-type="journal">
<person-group><name><surname>Mahavorasirikul</surname><given-names>W</given-names></name><name><surname>Tassaneeyakul</surname><given-names>W</given-names></name><name><surname>Satarug</surname><given-names>S</given-names></name><name><surname>Reungweerayut</surname><given-names>R</given-names></name><name><surname>Na-Bangchang</surname><given-names>C</given-names></name><name><surname>Na-Bangchang</surname><given-names>K</given-names></name></person-group>
<article-title>CYP2A6 genotypes and coumarin-oxidation phenotypes in a Thai population and their relationship to tobacco smoking</article-title>
<source>Eur J Clin Pharmacol</source>
<year>2009</year>
<volume>65</volume>
<fpage>377&#x02013;84</fpage>
<pub-id pub-id-type="pmid">19082995</pub-id></element-citation></ref><ref id="R80"><label>80</label><element-citation publication-type="journal">
<person-group><name><surname>Malaiyandi</surname><given-names>V</given-names></name><name><surname>Goodz</surname><given-names>SD</given-names></name><name><surname>Sellers</surname><given-names>EM</given-names></name><name><surname>Tyndale</surname><given-names>RF</given-names></name></person-group>
<article-title>CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during Ad libitum smoking</article-title>
<source>Cancer Epidemiol Biomarkers Prev</source>
<year>2006</year>
<volume>15</volume>
<fpage>1812&#x02013;9</fpage>
<pub-id pub-id-type="pmid">17035386</pub-id></element-citation></ref><ref id="R81"><label>81</label><element-citation publication-type="journal">
<person-group><name><surname>Malaiyandi</surname><given-names>V</given-names></name><name><surname>Lerman</surname><given-names>C</given-names></name><name><surname>Benowitz</surname><given-names>NL</given-names></name><name><surname>Jepson</surname><given-names>C</given-names></name><name><surname>Patterson</surname><given-names>F</given-names></name><name><surname>Tyndale</surname><given-names>RF</given-names></name></person-group>
<article-title>Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy</article-title>
<source>Mol Psychiatry</source>
<year>2006</year>
<volume>11</volume>
<fpage>400&#x02013;9</fpage>
<pub-id pub-id-type="pmid">16402128</pub-id></element-citation></ref><ref id="R82"><label>82</label><element-citation publication-type="journal">
<person-group><name><surname>Malaiyandi</surname><given-names>V</given-names></name><name><surname>Sellers</surname><given-names>EM</given-names></name><name><surname>Tyndale</surname><given-names>RF</given-names></name></person-group>
<article-title>Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence</article-title>
<source>Clin Pharmacol Ther</source>
<year>2005</year>
<volume>77</volume>
<fpage>145&#x02013;58</fpage>
<pub-id pub-id-type="pmid">15735609</pub-id></element-citation></ref><ref id="R83"><label>83</label><element-citation publication-type="journal">
<person-group><name><surname>Messina</surname><given-names>ES</given-names></name><name><surname>Tyndale</surname><given-names>RF</given-names></name><name><surname>Sellers</surname><given-names>EM</given-names></name></person-group>
<article-title>A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes</article-title>
<source>J Pharmacol Exp Ther</source>
<year>1997</year>
<volume>282</volume>
<fpage>1608&#x02013;14</fpage>
<pub-id pub-id-type="pmid">9316878</pub-id></element-citation></ref><ref id="R84"><label>84</label><element-citation publication-type="journal">
<person-group><name><surname>Minematsu</surname><given-names>N</given-names></name><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Furuuchi</surname><given-names>M</given-names></name><name><surname>Nakajima</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Tateno</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Limitation of cigarette consumption by CYP2A6*4, *7 and *9 polymorphisms</article-title>
<source>Eur Respir J</source>
<year>2006</year>
<volume>27</volume>
<fpage>289&#x02013;92</fpage>
<pub-id pub-id-type="pmid">16452582</pub-id></element-citation></ref><ref id="R85"><label>85</label><element-citation publication-type="journal">
<person-group><name><surname>Minematsu</surname><given-names>N</given-names></name><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Iwata</surname><given-names>M</given-names></name><name><surname>Tateno</surname><given-names>H</given-names></name><name><surname>Nakajima</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Association of CYP2A6 deletion polymorphism with smoking habit and development of pulmonary emphysema</article-title>
<source>Thorax</source>
<year>2003</year>
<volume>58</volume>
<fpage>623&#x02013;8</fpage>
<pub-id pub-id-type="pmid">12832682</pub-id></element-citation></ref><ref id="R86"><label>86</label><element-citation publication-type="journal">
<person-group><name><surname>Miyamoto</surname><given-names>M</given-names></name><name><surname>Umetsu</surname><given-names>Y</given-names></name><name><surname>Dosaka-Akita</surname><given-names>H</given-names></name><name><surname>Sawamura</surname><given-names>Y</given-names></name><name><surname>Yokota</surname><given-names>J</given-names></name><name><surname>Kunitoh</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>CYP2A6 gene deletion reduces susceptibility to lung cancer</article-title>
<source>Biochem Biophys Res Commun</source>
<year>1999</year>
<volume>261</volume>
<fpage>658&#x02013;60</fpage>
<pub-id pub-id-type="pmid">10441482</pub-id></element-citation></ref><ref id="R87"><label>87</label><element-citation publication-type="journal">
<person-group><name><surname>Mwenifumbo</surname><given-names>JC</given-names></name><name><surname>Al Koudsi</surname><given-names>N</given-names></name><name><surname>Man</surname><given-names>KH</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Hoffmann</surname><given-names>EB</given-names></name><name><surname>Sellers</surname><given-names>EM</given-names></name><etal/></person-group>
<article-title>Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of black African descent</article-title>
<source>Hum Mutat</source>
<year>2008</year>
<volume>29</volume>
<fpage>679&#x02013;88</fpage>
<pub-id pub-id-type="pmid">18360915</pub-id></element-citation></ref><ref id="R88"><label>88</label><element-citation publication-type="journal">
<person-group><name><surname>Mwenifumbo</surname><given-names>JC</given-names></name><name><surname>Myers</surname><given-names>MG</given-names></name><name><surname>Wall</surname><given-names>TL</given-names></name><name><surname>Lin</surname><given-names>S-K</given-names></name><name><surname>Sellers</surname><given-names>EM</given-names></name><name><surname>Tyndale</surname><given-names>RF</given-names></name></person-group>
<article-title>Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method</article-title>
<source>Pharmacogenet Genom</source>
<year>2005</year>
<volume>15</volume>
<fpage>189&#x02013;92</fpage>
</element-citation></ref><ref id="R89"><label>89</label><element-citation publication-type="journal">
<person-group><name><surname>Mwenifumbo</surname><given-names>JC</given-names></name><name><surname>Sellers</surname><given-names>EM</given-names></name><name><surname>Tyndale</surname><given-names>RF</given-names></name></person-group>
<article-title>Nicotine metabolism and CYP2A6 activity in a population of black African descent:Impact of gender and light smoking</article-title>
<source>Drug Alcohol Depend</source>
<year>2007</year>
<volume>89</volume>
<fpage>24&#x02013;33</fpage>
<pub-id pub-id-type="pmid">17161559</pub-id></element-citation></ref><ref id="R90"><label>90</label><element-citation publication-type="journal">
<person-group><name><surname>Mwenifumbo</surname><given-names>JC</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Benowitz</surname><given-names>NL</given-names></name><name><surname>Sellers</surname><given-names>EM</given-names></name><name><surname>Tyndale</surname><given-names>RF</given-names></name></person-group>
<article-title>New CYP2A6 gene deletion and conversion variants in a population of Black African descent</article-title>
<source>Pharmacogenomics</source>
<year>2010</year>
<volume>11</volume>
<fpage>189&#x02013;98</fpage>
<pub-id pub-id-type="pmid">20136358</pub-id></element-citation></ref><ref id="R91"><label>91</label><element-citation publication-type="journal">
<person-group><name><surname>Nakajima</surname><given-names>M</given-names></name><name><surname>Fukami</surname><given-names>T</given-names></name><name><surname>Yamanaka</surname><given-names>H</given-names></name><name><surname>Higashi</surname><given-names>E</given-names></name><name><surname>Sakai</surname><given-names>H</given-names></name><name><surname>Yoshida</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations</article-title>
<source>Clin Pharmacol Ther</source>
<year>2006</year>
<volume>80</volume>
<fpage>282&#x02013;97</fpage>
<pub-id pub-id-type="pmid">16952495</pub-id></element-citation></ref><ref id="R92"><label>92</label><element-citation publication-type="journal">
<person-group><name><surname>Nakajima</surname><given-names>M</given-names></name><name><surname>Kwon</surname><given-names>JT</given-names></name><name><surname>Tanaka</surname><given-names>N</given-names></name><name><surname>Zenta</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>Y</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans</article-title>
<source>Clin Pharmacol Ther</source>
<year>2001</year>
<volume>69</volume>
<fpage>72&#x02013;8</fpage>
<pub-id pub-id-type="pmid">11180041</pub-id></element-citation></ref><ref id="R93"><label>93</label><element-citation publication-type="journal">
<person-group><name><surname>Nakajima</surname><given-names>M</given-names></name><name><surname>Yamagishi</surname><given-names>S</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Kuroiwa</surname><given-names>Y</given-names></name><name><surname>Yokoi</surname><given-names>T</given-names></name></person-group>
<article-title>Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans</article-title>
<source>Clin Pharmacol Ther</source>
<year>2000</year>
<volume>67</volume>
<fpage>57&#x02013;69</fpage>
<pub-id pub-id-type="pmid">10668854</pub-id></element-citation></ref><ref id="R94"><label>94</label><element-citation publication-type="journal">
<person-group><name><surname>Nakajima</surname><given-names>M</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Nunoya</surname><given-names>K</given-names></name><name><surname>Yokoi</surname><given-names>T</given-names></name><name><surname>Nagashima</surname><given-names>K</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Role of human cytochrome P4502A6 in C-oxidation of nicotine</article-title>
<source>Drug Metab Dispos</source>
<year>1996</year>
<volume>24</volume>
<fpage>1212&#x02013;7</fpage>
<pub-id pub-id-type="pmid">8937855</pub-id></element-citation></ref><ref id="R95"><label>95</label><element-citation publication-type="journal">
<person-group><name><surname>Nakajima</surname><given-names>M</given-names></name><name><surname>Yoshida</surname><given-names>R</given-names></name><name><surname>Fukami</surname><given-names>T</given-names></name><name><surname>McLeod</surname><given-names>HL</given-names></name><name><surname>Yokoi</surname><given-names>T</given-names></name></person-group>
<article-title>Novel human CYP2A6 alleles confound gene deletion analysis</article-title>
<source>FEBS Lett</source>
<year>2004</year>
<volume>569</volume>
<fpage>75&#x02013;81</fpage>
<pub-id pub-id-type="pmid">15225612</pub-id></element-citation></ref><ref id="R96"><label>96</label><element-citation publication-type="journal">
<person-group><name><surname>Nowak</surname><given-names>MP</given-names></name><name><surname>Sellers</surname><given-names>EM</given-names></name><name><surname>Tyndale</surname><given-names>RF</given-names></name></person-group>
<article-title>Canadian native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies</article-title>
<source>Clin Pharmacol Ther</source>
<year>1998</year>
<volume>64</volume>
<fpage>378&#x02013;83</fpage>
<pub-id pub-id-type="pmid">9797794</pub-id></element-citation></ref><ref id="R97"><label>97</label><element-citation publication-type="journal">
<person-group><name><surname>Nunoya</surname><given-names>K</given-names></name><name><surname>Yokoi</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Kimura</surname><given-names>K</given-names></name><name><surname>Kinoshita</surname><given-names>M</given-names></name><name><surname>Kamataki</surname><given-names>T</given-names></name></person-group>
<article-title>Homologous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metabolizer phenotype</article-title>
<source>J Biochem</source>
<year>1999</year>
<volume>126</volume>
<fpage>402&#x02013;7</fpage>
<pub-id pub-id-type="pmid">10423536</pub-id></element-citation></ref><ref id="R98"><label>98</label><element-citation publication-type="journal">
<person-group><name><surname>Nurfadhlina</surname><given-names>M</given-names></name><name><surname>Foong</surname><given-names>K</given-names></name><name><surname>Teh</surname><given-names>LK</given-names></name><name><surname>Tan</surname><given-names>SC</given-names></name><name><surname>Mohd Zaki</surname><given-names>S</given-names></name><name><surname>Ismail</surname><given-names>R</given-names></name></person-group>
<article-title>CYP2A6 polymorphisms in Malays, Chinese and Indians</article-title>
<source>Xenobiotica</source>
<year>2006</year>
<volume>36</volume>
<fpage>684&#x02013;92</fpage>
<pub-id pub-id-type="pmid">16891249</pub-id></element-citation></ref><ref id="R99"><label>99</label><element-citation publication-type="journal">
<person-group><name><surname>O&#x02019;Loughlin</surname><given-names>J</given-names></name><name><surname>Paradis</surname><given-names>G</given-names></name><name><surname>Kim</surname><given-names>W</given-names></name><name><surname>DiFranza</surname><given-names>J</given-names></name><name><surname>Meshefedjian</surname><given-names>G</given-names></name><name><surname>McMillan-Davey</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers</article-title>
<source>Tob Control</source>
<year>2004</year>
<volume>13</volume>
<fpage>422&#x02013;8</fpage>
<pub-id pub-id-type="pmid">15564629</pub-id></element-citation></ref><ref id="R100"><label>100</label><element-citation publication-type="journal">
<person-group><name><surname>Oscarson</surname><given-names>M</given-names></name><name><surname>Gullst&#x000e9;n</surname><given-names>H</given-names></name><name><surname>Rautio</surname><given-names>A</given-names></name><name><surname>Bernal</surname><given-names>ML</given-names></name><name><surname>Sinues</surname><given-names>B</given-names></name><name><surname>Dahl</surname><given-names>ML</given-names></name><etal/></person-group>
<article-title>Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase</article-title>
<source>FEBS Lett</source>
<year>1998</year>
<volume>438</volume>
<fpage>201&#x02013;5</fpage>
<pub-id pub-id-type="pmid">9827545</pub-id></element-citation></ref><ref id="R101"><label>101</label><element-citation publication-type="journal">
<person-group><name><surname>Oscarson</surname><given-names>M</given-names></name><name><surname>McLellan</surname><given-names>RA</given-names></name><name><surname>Asp</surname><given-names>V</given-names></name><name><surname>Ledesma</surname><given-names>M</given-names></name><name><surname>Bernal Ruiz</surname><given-names>ML</given-names></name><name><surname>Sinues</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity</article-title>
<source>Hum Mutat</source>
<year>2002</year>
<volume>20</volume>
<fpage>275&#x02013;83</fpage>
<pub-id pub-id-type="pmid">12325023</pub-id></element-citation></ref><ref id="R102"><label>102</label><element-citation publication-type="journal">
<person-group><name><surname>Oscarson</surname><given-names>M</given-names></name><name><surname>McLellan</surname><given-names>RA</given-names></name><name><surname>Gullst&#x000e9;n</surname><given-names>H</given-names></name><name><surname>Ag&#x000fa;ndez</surname><given-names>JAG</given-names></name><name><surname>Ben&#x000ed;tez</surname><given-names>J</given-names></name><name><surname>Rautio</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Identification and characterisation of novel polymorphisms in the CYP2A locus:Implications for nicotine metabolism</article-title>
<source>FEBS Lett</source>
<year>1999</year>
<volume>460</volume>
<fpage>321&#x02013;7</fpage>
<pub-id pub-id-type="pmid">10544257</pub-id></element-citation></ref><ref id="R103"><label>103</label><element-citation publication-type="journal">
<person-group><name><surname>Oscarson</surname></name><name><surname>M</surname></name><name><surname>McLellan</surname><given-names>RA</given-names></name><name><surname>Gullst&#x000e9;n</surname><given-names>H</given-names></name><name><surname>Yue</surname><given-names>QY</given-names></name><name><surname>Lang</surname><given-names>MA</given-names></name><name><surname>Luisa Bernal</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population</article-title>
<source>FEBS Lett</source>
<year>1999</year>
<volume>448</volume>
<fpage>105&#x02013;10</fpage>
<pub-id pub-id-type="pmid">10217419</pub-id></element-citation></ref><ref id="R104"><label>104</label><element-citation publication-type="journal">
<person-group><name><surname>Pan</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Jia</surname><given-names>C</given-names></name></person-group>
<article-title>Association of CYP2A6 gene polymorphisms with cigarette consumption:A meta-analysis</article-title>
<source>Drug Alcohol Depend</source>
<year>2015</year>
<volume>149</volume>
<fpage>268&#x02013;71</fpage>
<pub-id pub-id-type="pmid">25683822</pub-id></element-citation></ref><ref id="R105"><label>105</label><element-citation publication-type="journal">
<person-group><name><surname>Pang</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>J-H</given-names></name><name><surname>Xu</surname><given-names>Y-S</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Dai</surname><given-names>P-G</given-names></name></person-group>
<article-title>The allele frequency of CYP2A6*4 in four ethnic groups of China</article-title>
<source>Exp Mol Pathol</source>
<year>2015</year>
<volume>98</volume>
<fpage>546&#x02013;8</fpage>
<pub-id pub-id-type="pmid">25862079</pub-id></element-citation></ref><ref id="R106"><label>106</label><element-citation publication-type="journal">
<person-group><name><surname>Paschke</surname><given-names>T</given-names></name><name><surname>Riefler</surname><given-names>M</given-names></name><name><surname>Schuler-Metz</surname><given-names>A</given-names></name><name><surname>Wolz</surname><given-names>L</given-names></name><name><surname>Scherer</surname><given-names>G</given-names></name><name><surname>McBride</surname><given-names>CM</given-names></name><etal/></person-group>
<article-title>Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method</article-title>
<source>Toxicology</source>
<year>2001</year>
<volume>168</volume>
<fpage>259&#x02013;68</fpage>
<pub-id pub-id-type="pmid">11684323</pub-id></element-citation></ref><ref id="R107"><label>107</label><element-citation publication-type="journal">
<person-group><name><surname>Peamkrasatam</surname><given-names>S</given-names></name><name><surname>Sriwatanakul</surname><given-names>K</given-names></name><name><surname>Kiyotani</surname><given-names>K</given-names></name><name><surname>Fujieda</surname><given-names>M</given-names></name><name><surname>Yamazaki</surname><given-names>H</given-names></name><name><surname>Kamataki</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais</article-title>
<source>Drug Metab Pharmacokinet</source>
<year>2006</year>
<volume>21</volume>
<fpage>475&#x02013;84</fpage>
<pub-id pub-id-type="pmid">17220563</pub-id></element-citation></ref><ref id="R108"><label>108</label><element-citation publication-type="journal">
<person-group><name><surname>P&#x000e9;rez-Rubio</surname><given-names>G</given-names></name><name><surname>Sansores</surname><given-names>R</given-names></name><name><surname>Ram&#x000ed;rez-Venegas</surname><given-names>A</given-names></name><name><surname>Camarena</surname><given-names>&#x000c1;</given-names></name><name><surname>P&#x000e9;rez-Rodr&#x000ed;guez</surname><given-names>ME</given-names></name><name><surname>Falf&#x000e1;n-Valencia</surname><given-names>R</given-names></name></person-group>
<article-title>Nicotine addiction development: from epidemiology to genetic factors</article-title>
<source>Rev Investig Cl&#x000ed;n</source>
<year>2015</year>
<volume>67</volume>
<fpage>333</fpage>
<lpage>334</lpage>
<pub-id pub-id-type="pmid">26950737</pub-id></element-citation></ref><ref id="R109"><label>109</label><element-citation publication-type="journal">
<person-group><name><surname>Piliguian</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>AZX</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Benowitz</surname><given-names>NL</given-names></name><name><surname>Ahluwalia</surname><given-names>JS</given-names></name><name><surname>Cox</surname><given-names>LS</given-names></name><etal/></person-group>
<article-title>Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo</article-title>
<source>Pharmacogenet Genom</source>
<year>2014</year>
<volume>24</volume>
<fpage>118&#x02013;28</fpage>
</element-citation></ref><ref id="R110"><label>110</label><element-citation publication-type="journal">
<person-group><name><surname>Pitarque</surname><given-names>M</given-names></name><name><surname>von Richter</surname><given-names>O</given-names></name><name><surname>Oke</surname><given-names>B</given-names></name><name><surname>Berkkan</surname><given-names>H</given-names></name><name><surname>Oscarson</surname><given-names>M</given-names></name><name><surname>Ingelman-Sundberg</surname><given-names>M</given-names></name></person-group>
<article-title>Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene:impairment of its promoter activity</article-title>
<source>Biochem Biophys Res Commun</source>
<year>2001</year>
<volume>284</volume>
<fpage>455&#x02013;60</fpage>
<pub-id pub-id-type="pmid">11394901</pub-id></element-citation></ref><ref id="R111"><label>111</label><element-citation publication-type="journal">
<person-group><name><surname>Pitarque</surname><given-names>M</given-names></name><name><surname>von Richter</surname><given-names>O</given-names></name><name><surname>Rodr&#x000ed;guez-Antona</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Oscarson</surname><given-names>M</given-names></name><name><surname>Ingelman-Sundberg</surname><given-names>M</given-names></name></person-group>
<article-title>A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity</article-title>
<source>Hum Mutat</source>
<year>2004</year>
<volume>23</volume>
<fpage>258&#x02013;66</fpage>
<pub-id pub-id-type="pmid">14974084</pub-id></element-citation></ref><ref id="R112"><label>112</label><element-citation publication-type="journal">
<person-group><name><surname>Rao</surname><given-names>Y</given-names></name><name><surname>Hoffmann</surname><given-names>E</given-names></name><name><surname>Zia</surname><given-names>M</given-names></name><name><surname>Bodin</surname><given-names>L</given-names></name><name><surname>Zeman</surname><given-names>M</given-names></name><name><surname>Sellers</surname><given-names>EM</given-names></name><etal/></person-group>
<article-title>Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking</article-title>
<source>Mol Pharmacol</source>
<year>2000</year>
<volume>58</volume>
<fpage>747&#x02013;55</fpage>
<pub-id pub-id-type="pmid">10999944</pub-id></element-citation></ref><ref id="R113"><label>113</label><element-citation publication-type="journal">
<person-group><name><surname>Ray</surname><given-names>R</given-names></name><name><surname>Tyndale</surname><given-names>RF</given-names></name><name><surname>Lerman</surname><given-names>C</given-names></name></person-group>
<article-title>Nicotine dependence pharmacogenetics:role of genetic variation in nicotine-metabolizing enzymes</article-title>
<source>J Neurogenet</source>
<year>2009</year>
<volume>23</volume>
<fpage>252</fpage>
<lpage>261</lpage>
<pub-id pub-id-type="pmid">19169923</pub-id></element-citation></ref><ref id="R114"><label>114</label><element-citation publication-type="journal">
<person-group><name><surname>Roco</surname><given-names>&#x000c1;</given-names></name><name><surname>Qui&#x000f1;ones</surname><given-names>L</given-names></name><name><surname>Ag&#x000fa;ndez</surname><given-names>JAG</given-names></name><name><surname>Garc&#x000ed;a-Mart&#x000ed;n</surname><given-names>E</given-names></name><name><surname>Squicciarini</surname><given-names>V</given-names></name><name><surname>Miranda</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the Chilean population: comparison with Caucasian and Asian populations</article-title>
<source>Front Genet</source>
<year>2012</year>
<volume>3</volume>
<fpage>1&#x02013;9</fpage>
<pub-id pub-id-type="pmid">22303408</pub-id></element-citation></ref><ref id="R115"><label>115</label><element-citation publication-type="journal">
<person-group><name><surname>Rossini</surname><given-names>A</given-names></name><name><surname>Soares Lima</surname><given-names>S</given-names></name><name><surname>Rapozo</surname><given-names>DCM</given-names></name><name><surname>Faria</surname><given-names>M</given-names></name><name><surname>Albano</surname><given-names>RM</given-names></name><name><surname>Ribeiro Pinto</surname><given-names>LF</given-names></name></person-group>
<article-title>CYP2A6 and CYP2E1 polymorphisms in a Brazilian population living in Rio de Janeiro</article-title>
<source>Braz J Med Biol Res</source>
<year>2006</year>
<volume>39</volume>
<fpage>195&#x02013;201</fpage>
<pub-id pub-id-type="pmid">16470306</pub-id></element-citation></ref><ref id="R116"><label>116</label><element-citation publication-type="journal">
<person-group><name><surname>Sabol</surname><given-names>SZ</given-names></name><name><surname>Hamer</surname><given-names>DH</given-names></name></person-group>
<article-title>An improved assay shows no association between the CYP2A6 gene and cigarette smoking behaviour</article-title>
<source>Behav Genet</source>
<year>1999</year>
<volume>157</volume>
<fpage>632&#x02013;4</fpage>
</element-citation></ref><ref id="R117"><label>117</label><element-citation publication-type="journal">
<person-group><name><surname>Schoedel</surname><given-names>KA</given-names></name><name><surname>Hoffmann</surname><given-names>EB</given-names></name><name><surname>Rao</surname><given-names>Y</given-names></name><name><surname>Sellers</surname><given-names>EM</given-names></name><name><surname>Tyndale</surname><given-names>RF</given-names></name></person-group>
<article-title>Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians</article-title>
<source>Pharmacogenetics</source>
<year>2004</year>
<volume>14</volume>
<fpage>615&#x02013;26</fpage>
<pub-id pub-id-type="pmid">15475735</pub-id></element-citation></ref><ref id="R118"><label>118</label><element-citation publication-type="journal">
<person-group><name><surname>Schulz</surname><given-names>TG</given-names></name><name><surname>Ruhnau</surname><given-names>P</given-names></name><name><surname>Hallier</surname><given-names>E</given-names></name></person-group>
<article-title>Lack of correlation between CYP2A6 genotype and smoking habits</article-title>
<source>Adv Exp Med Biol</source>
<year>2001</year>
<volume>500</volume>
<fpage>213&#x02013;5</fpage>
<pub-id pub-id-type="pmid">11764938</pub-id></element-citation></ref><ref id="R119"><label>119</label><element-citation publication-type="journal">
<person-group><name><surname>Sepehr</surname><given-names>A</given-names></name><name><surname>Kamangar</surname><given-names>F</given-names></name><name><surname>Abnet</surname><given-names>CC</given-names></name><name><surname>Fahimi</surname><given-names>S</given-names></name><name><surname>Pourshams</surname><given-names>A</given-names></name><name><surname>Poustchi</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Genetic polymorphisms in three Iranian populations with different risks of esophageal cancer, an ecologic comparison</article-title>
<source>Cancer Lett</source>
<year>2004</year>
<volume>213</volume>
<fpage>195&#x02013;202</fpage>
<pub-id pub-id-type="pmid">15327835</pub-id></element-citation></ref><ref id="R120"><label>120</label><element-citation publication-type="journal">
<person-group><name><surname>Shimada</surname><given-names>T</given-names></name><name><surname>Yamazaki</surname><given-names>H</given-names></name><name><surname>Guengerich</surname><given-names>FP</given-names></name></person-group>
<article-title>Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations</article-title>
<source>Xenobiotica</source>
<year>1996</year>
<volume>26</volume>
<fpage>395&#x02013;403</fpage>
<pub-id pub-id-type="pmid">9173680</pub-id></element-citation></ref><ref id="R121"><label>121</label><element-citation publication-type="journal">
<person-group><name><surname>Sim</surname><given-names>SC</given-names></name><name><surname>Ingelman-Sundberg</surname><given-names>M</given-names></name></person-group>
<article-title>The human cyto-chrome P450 (CYP) allele nomenclature website: a peer-reviewed database of CYP variants and their as-sociated effects</article-title>
<source>Hum Genom</source>
<year>2010</year>
<volume>4</volume>
<fpage>278&#x02013;81</fpage>
</element-citation></ref><ref id="R122"><label>122</label><element-citation publication-type="journal">
<person-group><name><surname>Sim</surname><given-names>SC</given-names></name><name><surname>Ingelman-Sundberg</surname><given-names>M</given-names></name></person-group>
<article-title>Update on allele no-menclature for human cytochromes P450 and the human cytochrome P450 allele (CYP-allele) nomen-clature database</article-title>
<source>Methods Mol Biol</source>
<year>2013</year>
<volume>987</volume>
<fpage>251</fpage>
<lpage>259</lpage>
<pub-id pub-id-type="pmid">23475683</pub-id></element-citation></ref><ref id="R123"><label>123</label><element-citation publication-type="journal">
<person-group><name><surname>Song</surname><given-names>D-K</given-names></name><name><surname>Xing</surname><given-names>D-L</given-names></name><name><surname>Zhang</surname><given-names>L-R</given-names></name><name><surname>Li</surname><given-names>Z-X</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Qiao</surname><given-names>B-P</given-names></name></person-group>
<article-title>Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China</article-title>
<source>Cancer Detect Prev</source>
<year>2009</year>
<volume>32</volume>
<fpage>416&#x02013;23</fpage>
<pub-id pub-id-type="pmid">19303722</pub-id></element-citation></ref><ref id="R124"><label>124</label><element-citation publication-type="journal">
<person-group><name><surname>Soriano</surname><given-names>A</given-names></name><name><surname>Vicente</surname><given-names>J</given-names></name><name><surname>Carcas</surname><given-names>C</given-names></name><name><surname>Gonzalez-Andrade</surname><given-names>F</given-names></name><name><surname>Arenaz</surname><given-names>I</given-names></name><name><surname>Martinez-Jarreta</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Differences between Spaniards and Ecuadorians in CYP2A6 allele frequencies: comparison with other populations</article-title>
<source>Fund Clin Pharmacol</source>
<year>2011</year>
<volume>25</volume>
<fpage>627&#x02013;32</fpage>
</element-citation></ref><ref id="R125"><label>125</label><element-citation publication-type="journal">
<person-group><name><surname>Strasser</surname><given-names>AA</given-names></name><name><surname>Benowitz</surname><given-names>NL</given-names></name><name><surname>Pinto</surname><given-names>AG</given-names></name><name><surname>Tang</surname><given-names>KZ</given-names></name><name><surname>Hecht</surname><given-names>SS</given-names></name><name><surname>Carmella</surname><given-names>SG</given-names></name><etal/></person-group>
<article-title>Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level</article-title>
<source>Cancer Epidemiol Biomarkers Prev</source>
<year>2011</year>
<volume>20</volume>
<fpage>234&#x02013;8</fpage>
<pub-id pub-id-type="pmid">21212060</pub-id></element-citation></ref><ref id="R126"><label>126</label><element-citation publication-type="journal">
<person-group><name><surname>Svyryd</surname><given-names>Y</given-names></name><name><surname>Ram&#x000ed;rez-Venegas</surname><given-names>A</given-names></name><name><surname>S&#x000e1;nchez-Hern&#x000e1;ndez</surname><given-names>B</given-names></name><name><surname>Aguayo-G&#x000f3;mez</surname><given-names>A</given-names></name><name><surname>Luna-Mu&#x000f1;oz</surname><given-names>L</given-names></name><name><surname>Arteaga-V&#x000e1;zquez</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Genetic risk determinants for cigarette smoking dependence in Mexican estizo families</article-title>
<source>Nicotine Tob Res</source>
<year>2015</year>
<volume>18</volume>
<fpage>620&#x02013;5</fpage>
<pub-id pub-id-type="pmid">26416825</pub-id></element-citation></ref><ref id="R127"><label>127</label><element-citation publication-type="journal">
<person-group><name><surname>Swan</surname><given-names>GE</given-names></name><name><surname>Benowitz</surname><given-names>NL</given-names></name><name><surname>Lessov</surname><given-names>CN</given-names></name><name><surname>Jacob</surname><given-names>P</given-names></name><name><surname>Tyndale</surname><given-names>RF</given-names></name><name><surname>Wilhelmsen</surname><given-names>K</given-names></name></person-group>
<article-title>Nicotine metabolism:the impact of CYP2A6 on estimates of additive genetic influence</article-title>
<source>Pharmacogenet Genom</source>
<year>2005</year>
<volume>15</volume>
<fpage>115&#x02013;25</fpage>
</element-citation></ref><ref id="R128"><label>128</label><element-citation publication-type="journal">
<person-group><name><surname>Swan</surname><given-names>GE</given-names></name><name><surname>Jack</surname><given-names>LM</given-names></name><name><surname>Ward</surname><given-names>MM</given-names></name></person-group>
<article-title>Subgroups of smokers with different success rates after use of transdermal nicotine</article-title>
<source>Addiction</source>
<year>1997</year>
<volume>92</volume>
<fpage>207&#x02013;17</fpage>
<pub-id pub-id-type="pmid">9158232</pub-id></element-citation></ref><ref id="R129"><label>129</label><element-citation publication-type="journal">
<person-group><name><surname>Takeshita</surname><given-names>H</given-names></name><name><surname>Hieda</surname><given-names>Y</given-names></name><name><surname>Fujihara</surname><given-names>J</given-names></name><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>Nakagami</surname><given-names>N</given-names></name><name><surname>Takayama</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>CYP2A6 polymorphism reveals differences in Japan and the existence of a specific variant in Ovambo and Turk populations</article-title>
<source>Hum Biol</source>
<year>2006</year>
<volume>78</volume>
<fpage>235&#x02013;42</fpage>
<pub-id pub-id-type="pmid">17036930</pub-id></element-citation></ref><ref id="R130"><label>130</label><element-citation publication-type="journal">
<person-group><name><surname>Tamaki</surname><given-names>Y</given-names></name><name><surname>Arai</surname><given-names>T</given-names></name><name><surname>Sugimura</surname><given-names>H</given-names></name><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Honda</surname><given-names>M</given-names></name><name><surname>Muroi</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Association between cancer risk and drug-metabolizing enzyme gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in cases of lung cancer in Japan</article-title>
<source>Drug Metab Pharmacokinet</source>
<year>2011</year>
<volume>26</volume>
<fpage>516&#x02013;22</fpage>
<pub-id pub-id-type="pmid">21791872</pub-id></element-citation></ref><ref id="R131"><label>131</label><element-citation publication-type="journal">
<person-group><name><surname>Tan</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>GF</given-names></name><name><surname>Xing</surname><given-names>DY</given-names></name><name><surname>Song</surname><given-names>CY</given-names></name><name><surname>Kadlubar</surname><given-names>FF</given-names></name><name><surname>Lin</surname><given-names>DX</given-names></name></person-group>
<article-title>Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population</article-title>
<source>Int J Cancer</source>
<year>2001</year>
<volume>95</volume>
<fpage>96&#x02013;101</fpage>
<pub-id pub-id-type="pmid">11241319</pub-id></element-citation></ref><ref id="R132"><label>132</label><element-citation publication-type="journal">
<person-group><name><surname>Thorgeirsson</surname><given-names>TE</given-names></name><name><surname>Gudbjartsson</surname><given-names>DF</given-names></name><name><surname>Surakka</surname><given-names>I</given-names></name><name><surname>Vink</surname><given-names>JM</given-names></name><name><surname>Amin</surname><given-names>N</given-names></name><name><surname>Geller</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior</article-title>
<source>Nat Genet</source>
<year>2010</year>
<volume>42</volume>
<fpage>448&#x02013;53</fpage>
<pub-id pub-id-type="pmid">20418888</pub-id></element-citation></ref><ref id="R133"><label>133</label><element-citation publication-type="journal">
<person-group><name><surname>Tiihonen</surname><given-names>J</given-names></name><name><surname>Pesonen</surname><given-names>U</given-names></name><name><surname>Kauhanen</surname><given-names>J</given-names></name><name><surname>Koulu</surname><given-names>M</given-names></name><name><surname>Hallikainen</surname><given-names>T</given-names></name><name><surname>Leskinen</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>CYP2A6 genotype and smoking</article-title>
<source>Mol Psychiatry</source>
<year>2000</year>
<volume>5</volume>
<fpage>347&#x02013;8</fpage>
<pub-id pub-id-type="pmid">10889542</pub-id></element-citation></ref><ref id="R134"><label>134</label><element-citation publication-type="journal">
<person-group><name><surname>Tiong</surname><given-names>KH</given-names></name><name><surname>Mohammed Yunus</surname><given-names>NA</given-names></name><name><surname>Yiap</surname><given-names>BC</given-names></name><name><surname>Tan</surname><given-names>EL</given-names></name><name><surname>Ismail</surname><given-names>R</given-names></name><name><surname>Ong</surname><given-names>CE</given-names></name></person-group>
<article-title>Inhibitory potency of 8-methoxypsoralen on cytochrome P450 2A6 (CYP2A6) allelic variants CYP2A6 15, CYP2A6 16, CYP2A6 21 and CYP2A6 22: differential susceptibility due to different sequence locations of the mutations</article-title>
<source>PloS One</source>
<year>2014</year>
<volume>9</volume>
<fpage>e86230</fpage>
<pub-id pub-id-type="pmid">24475091</pub-id></element-citation></ref><ref id="R135"><label>135</label><element-citation publication-type="journal">
<person-group><name><surname>Tiong</surname><given-names>KH</given-names></name><name><surname>Yiap</surname><given-names>BC</given-names></name><name><surname>Tan</surname><given-names>EL</given-names></name><name><surname>Ismail</surname><given-names>R</given-names></name><name><surname>Ong</surname><given-names>CE</given-names></name></person-group>
<article-title>Func-tional characterization of cytochrome P450 2A6 allel-ic variants CYP2A6*15, CYP2A6 *16, CYP2A6*21, and CYP2A6*22</article-title>
<source>Drug Metab Dispos</source>
<year>2010</year>
<volume>38</volume>
<fpage>745&#x02013;51</fpage>
<pub-id pub-id-type="pmid">20139165</pub-id></element-citation></ref><ref id="R136"><label>136</label><element-citation publication-type="journal">
<person-group><name><surname>Tiwawech</surname><given-names>D</given-names></name><name><surname>Srivatanakul</surname><given-names>P</given-names></name><name><surname>Karalak</surname><given-names>A</given-names></name><name><surname>Ishida</surname><given-names>T</given-names></name></person-group>
<article-title>Cytochrome P450 2A6 polymorphism in nasopha-ryngeal carcinoma</article-title>
<source>Cancer Lett</source>
<year>2006</year>
<volume>241</volume>
<fpage>135&#x02013;41</fpage>
<pub-id pub-id-type="pmid">16377082</pub-id></element-citation></ref><ref id="R137"><label>137</label><element-citation publication-type="journal">
<person-group><name><surname>Topcu</surname><given-names>Z</given-names></name><name><surname>Chiba</surname><given-names>I</given-names></name><name><surname>Fujieda</surname><given-names>M</given-names></name><name><surname>Shibata</surname><given-names>T</given-names></name><name><surname>Ariyoshi</surname><given-names>N</given-names></name><name><surname>Yamazaki</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>CYP2A6 gene deletion reduces oral cancer risk in betel quid chewers in Sri Lanka</article-title>
<source>Carcinogenesis</source>
<year>2002</year>
<volume>23</volume>
<fpage>595&#x02013;8</fpage>
<pub-id pub-id-type="pmid">11960911</pub-id></element-citation></ref><ref id="R138"><label>138</label><element-citation publication-type="journal">
<person-group><name><surname>Uno</surname><given-names>T</given-names></name><name><surname>Obe</surname><given-names>Y</given-names></name><name><surname>Ogura</surname><given-names>C</given-names></name><name><surname>Goto</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Metabolism of 7-ethoxycoumarin, safrole, flavanone and hydroxyflavanone by cytochrome P450 2A6 variants</article-title>
<source>Biopharm Drug Dispos</source>
<year>2013</year>
<volume>34</volume>
<fpage>87&#x02013;97</fpage>
<pub-id pub-id-type="pmid">23112005</pub-id></element-citation></ref><ref id="R139"><label>139</label><element-citation publication-type="journal">
<person-group><name><surname>Vasconcelos</surname><given-names>GM</given-names></name><name><surname>Struchiner</surname><given-names>CJ</given-names></name><name><surname>Suarez-Kurtz</surname><given-names>G</given-names></name></person-group>
<article-title>CYP2A6 genetic polymorphisms and correlation with smoking status in Brazilians</article-title>
<source>Pharmacogenom J</source>
<year>2005</year>
<volume>5</volume>
<fpage>42&#x02013;8</fpage>
</element-citation></ref><ref id="R140"><label>140</label><element-citation publication-type="journal">
<person-group><name><surname>Veiga</surname><given-names>MI</given-names></name><name><surname>Asimus</surname><given-names>S</given-names></name><name><surname>Ferreira</surname><given-names>PE</given-names></name><name><surname>Martins</surname><given-names>JP</given-names></name><name><surname>Cavaco</surname><given-names>I</given-names></name><name><surname>Ribeiro</surname><given-names>V</given-names></name><etal/></person-group>
<article-title>Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam</article-title>
<source>Eur J Clin Pharmacol</source>
<year>2009</year>
<volume>65</volume>
<fpage>355&#x02013;63</fpage>
<pub-id pub-id-type="pmid">18979093</pub-id></element-citation></ref><ref id="R141"><label>141</label><element-citation publication-type="journal">
<person-group><name><surname>Verde Rello</surname><given-names>Z</given-names></name><name><surname>Santiago Dorrego</surname><given-names>C</given-names></name></person-group>
<article-title>Gene genetics of the tobacco smoking</article-title>
<source>Med Cl&#x000ed;n (Barcelona)</source>
<year>2013</year>
<volume>140</volume>
<fpage>66&#x02013;7</fpage>
</element-citation></ref><ref id="R142"><label>142</label><element-citation publication-type="journal">
<person-group><name><surname>von Richter</surname><given-names>O</given-names></name><name><surname>Pitarque</surname><given-names>M</given-names></name><name><surname>Rodr&#x000ed;guez-Antona</surname><given-names>C</given-names></name><name><surname>Testa</surname><given-names>A</given-names></name><name><surname>Mantovani</surname><given-names>R</given-names></name><name><surname>Oscarson</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6)</article-title>
<source>Pharmacogenetics</source>
<year>2004</year>
<volume>14</volume>
<fpage>369&#x02013;79</fpage>
<pub-id pub-id-type="pmid">15247629</pub-id></element-citation></ref><ref id="R143"><label>143</label><element-citation publication-type="journal">
<person-group><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Pitarque</surname><given-names>M</given-names></name><name><surname>Ingelman-Sundberg</surname><given-names>M</given-names></name></person-group>
<article-title>3&#x02019;-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression</article-title>
<source>Biochem Biophys Res Commun</source>
<year>2006</year>
<volume>340</volume>
<fpage>491&#x02013;7</fpage>
<pub-id pub-id-type="pmid">16378601</pub-id></element-citation></ref><ref id="R144"><label>144</label><element-citation publication-type="journal">
<person-group><name><surname>Wassenaar</surname><given-names>CA</given-names></name><name><surname>Dong</surname><given-names>Q</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name><name><surname>Amos</surname><given-names>CI</given-names></name><name><surname>Spitz</surname><given-names>MR</given-names></name><name><surname>Tyndale</surname><given-names>RF</given-names></name></person-group>
<article-title>Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk</article-title>
<source>J Natl Cancer Inst</source>
<year>2011</year>
<volume>103</volume>
<fpage>1342&#x02013;6</fpage>
<pub-id pub-id-type="pmid">21747048</pub-id></element-citation></ref><ref id="R145"><label>145</label><element-citation publication-type="journal">
<person-group><name><surname>Wassenaar</surname><given-names>CA</given-names></name><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>Q</given-names></name><name><surname>Aldrich</surname><given-names>MC</given-names></name><name><surname>Knight</surname><given-names>J</given-names></name><name><surname>Spitz</surname><given-names>MR</given-names></name><etal/></person-group>
<article-title>CYP2A6 reduced activity gene variants confer reduction in lung cancer risk in African American smokers-findings from two independent populations</article-title>
<source>Carcinogenesis</source>
<year>2015</year>
<volume>36</volume>
<fpage>99&#x02013;103</fpage>
<pub-id pub-id-type="pmid">25416559</pub-id></element-citation></ref><ref id="R146"><label>146</label><element-citation publication-type="book">
<collab>WHO, World Health Organization</collab>
<article-title>WHO report on the global tobacco epidemic, 2011</article-title>
<year>2011</year>
<publisher-name>World Health Organization</publisher-name>
<comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/tobacco/global_report/2011/en/.">http://www.who.int/tobacco/global_report/2011/en/.</ext-link></comment>
</element-citation></ref><ref id="R147"><label>147</label><element-citation publication-type="journal">
<person-group><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Rao</surname><given-names>YS</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Hoffmann</surname><given-names>E</given-names></name><name><surname>Jones</surname><given-names>J</given-names></name><name><surname>Sellers</surname><given-names>EM</given-names></name><etal/></person-group>
<article-title>An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles</article-title>
<source>Biochem Biophys Res Commun</source>
<year>2002</year>
<volume>290</volume>
<fpage>318&#x02013;24</fpage>
<pub-id pub-id-type="pmid">11779172</pub-id></element-citation></ref><ref id="R148"><label>148</label><element-citation publication-type="journal">
<person-group><name><surname>Yamano</surname><given-names>S</given-names></name><name><surname>Tatsuno</surname><given-names>J</given-names></name><name><surname>Gonzalez</surname><given-names>FJ</given-names></name></person-group>
<article-title>The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes</article-title>
<source>Biochemistry</source>
<year>1990</year>
<volume>29</volume>
<fpage>1322&#x02013;9</fpage>
<pub-id pub-id-type="pmid">2322567</pub-id></element-citation></ref><ref id="R149"><label>149</label><element-citation publication-type="journal">
<person-group><name><surname>Yoshida</surname><given-names>R</given-names></name><name><surname>Nakajima</surname><given-names>M</given-names></name><name><surname>Nishimura</surname><given-names>K</given-names></name><name><surname>Tokudome</surname><given-names>S</given-names></name><name><surname>Kwon</surname><given-names>JT</given-names></name><name><surname>Yokoi</surname><given-names>T</given-names></name></person-group>
<article-title>Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro</article-title>
<source>Clin Pharmacol Ther</source>
<year>2003</year>
<volume>74</volume>
<fpage>69&#x02013;76</fpage>
<pub-id pub-id-type="pmid">12844137</pub-id></element-citation></ref><ref id="R150"><label>150</label><element-citation publication-type="journal">
<person-group><name><surname>Yoshida</surname><given-names>R</given-names></name><name><surname>Nakajima</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>Y</given-names></name><name><surname>Kwon</surname><given-names>JT</given-names></name><name><surname>Yokoi</surname><given-names>T</given-names></name></person-group>
<article-title>Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism</article-title>
<source>Br J Clin Pharmacol</source>
<year>2002</year>
<volume>54</volume>
<fpage>511&#x02013;7</fpage>
<pub-id pub-id-type="pmid">12445030</pub-id></element-citation></ref><ref id="R151"><label>151</label><element-citation publication-type="journal">
<person-group><name><surname>Yuan</surname><given-names>J-M</given-names></name><name><surname>Nelson</surname><given-names>HH</given-names></name><name><surname>Butler</surname><given-names>LM</given-names></name><name><surname>Carmella</surname><given-names>SG</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Kuriger-Laber</surname><given-names>JK</given-names></name><etal/></person-group>
<article-title>Genetic determinants of cytochrome P450 2A6 activity and biomarkers of tobacco smoke exposure in relation to risk of lung cancer development in the Shanghai cohort study</article-title>
<source>Int J Cancer</source>
<year>2016</year>
<volume>138</volume>
<fpage>2161&#x02013;71</fpage>
<pub-id pub-id-type="pmid">26662855</pub-id></element-citation></ref><ref id="R152"><label>152</label><element-citation publication-type="journal">
<person-group><name><surname>Yusof</surname><given-names>W</given-names></name><name><surname>Gan</surname><given-names>SH</given-names></name></person-group>
<article-title>High prevalence of CYP2A6*4 and CYP2A6*9 alleles detected among a Malaysian population</article-title>
<source>Clin Chim Acta</source>
<year>2009</year>
<volume>403</volume>
<fpage>105&#x02013;9</fpage>
<pub-id pub-id-type="pmid">19361454</pub-id></element-citation></ref><ref id="R153"><label>153</label><element-citation publication-type="journal">
<person-group><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Amemo</surname><given-names>K</given-names></name><name><surname>Ameno</surname><given-names>S</given-names></name><name><surname>Iwahashi</surname><given-names>K</given-names></name><name><surname>Kinoshita</surname><given-names>H</given-names></name><name><surname>Kubota</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Lack of association between smoking and CYP2A6 gene polymorphisms in A Japanese population</article-title>
<source>Nihon Arukoru Yakubutsu Igakkai Zasshi</source>
<year>2001</year>
<volume>36</volume>
<fpage>486&#x02013;90</fpage>
<pub-id pub-id-type="pmid">11725533</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title><italic>CYP2A6</italic> location and mutations in the gene. Mutations are reported by the <italic>Human CYP-Allele Nomenclature Database </italic>(http://www.cypalleles.ki.se) and include insertion, deletion, CNV and SNP. Ref Seq NG_008377.1</title></caption><graphic xlink:href="EXCLI-16-174-g-001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title><italic>CYP2A6</italic> alleles reported in tobacco consumption related studies. Number of <italic>CYP2A6</italic> alleles that have reported frequencies in population and association studies related to tobacco/nicotine consumption and cancer related to tobacco consumption (in the population study). </title><p>The populations are grouped according to possible ancestral and / or geographical origin: African (Canadian, American, Ghanaian, Ethiopian, Namibian, &#x0201c;African&#x0201d; and &#x0201c;Black&#x0201d; populations). Caucasian (German, Canadian, American, Spanish, Finish, French, Hungarian, English, Serbian, Swedish, &#x0201c;Caucasian&#x0201d; and &#x0201c;Whites&#x0201d;). East Asian (Chinese, Korean, Japanese, Malaysia, Thai, Taiwanese, Vietnamese, Han Chinese, Uighur, Bouyei, Tibetan, Shimane, Tottori, Fukuoka, Ehime and &#x0201c;Asian&#x0201d;) South Asian (Indian, Bangladeshi, Sri Lanka, Tamilian, Kannadika, Keralites and Andhrites). Middle East (Iranian, Turkish, Tatar, Turks, Turkomans and Zoroastrian Persians). American Continent (Hispanic, Brazilian, Chilean, Ecuadorian, Mexican, Canadian Native and Alaskan Yupik). Oceania (Neo Zealander M&#x00101;ori). *Except African American, American and Canadian.</p></caption><graphic xlink:href="EXCLI-16-174-g-002"/></fig></floats-group></article>